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ENHANCEMENT OF CHEMICALLY-
INDUCED NEOPLASIA BY PROXI-
MAL ENTERECTOMY. R. C. N. WIL-
LIAMSON, F. L. R. BAUER and R. A. MALT,
United Bristol Hospitals and MlVassachusetts
General Hospital, Boston, U.S.A. (Introduced
by M. 0. Symes).
Azoxymethane-induced tumours in the
rat, morphologically indistinguishable from
those arising in man, affect the duodenum,
jejunum and colon, but usually spare the
ileum (Ward, J. M. (1975) Vet. Pathol., 12,
165). Proximal small-bowel resection (PSBR)
causes prompt ileal hyperplasia, with a lesser
response in the colon. To test the possible
adjuvant effect of postresectional hyper-
plasia on intestinal carcinogenesis, rats
(n= 76) were submitted to 5000 PSBR 10
days after the last of 16 weekly injections of
azoxymethane (10 mg/kg s.c.) or vehicle.
Controls were unoperated. Nucleic acid
contents of upper ileal mucosa in rats receiv-
ing vehicle alone showed increments of 76%
(RNA) and 680, (DNA) 3 nionths after
PSBR (P < 0-001). The number and distri-
bution of intestinal tumours were noted in
rats sacrificed at 30 weeks, or dying of cancer
in the preceding 4 weeks. Intestinal tumours
occurred in all but 1 of the rats receiving
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azoxymethane, but in none of those injected
with vehicle. Proximal enterectomy raised
the incidence of colonic tumours but failed to
induce ileal carcinogenesis, despite promoting
marked mucosal hyperplasia. We conclude
that postresectional hyperplasia cannot over-
come the relative insusceptibility of the ileum
to neoplasia, but that it enhances the induc-
tion of tumours in colon previously exposed
to chemical carcinogens.
AN INVESTIGATION OF ETHYL-
NITROSOUREA-INDUCED CARCINO-
GENESIS IN THE RAT BRAIN BY AN
IN VIVO-IN VITRO METHOD. J. P.
RoSCOE and P. J. CLAISSE, Department of
Cell Pathology, School of Pathology, Middlesex
Hospital Medical School.
Pregnant rats were injected with ethyl-
nitrosourea to induce cerebral gliomas in a
high proportion of the offspring. With a dose
of 40-50 mg/kg body weight the average
latent period for these brain tumours is 246
days. Cultures have been prepared at
different times after transplacental exposure
but before a tumour is visible. It has been
reported previously (Roscoe and Claisse
(1976) Nature, Lond., 262, 314) that there is
a marked difference in the behaviour of
cultures prepared 138-145 days p.i. and 2
days p.i. These experiments have been
extended and are reported here. Cultures
prepared 111-112 days p.i. were similar to
those derived 138-145 days p.i. They con-
tained cells like those found in tumour
cultures which can predominate in culture
and are tumourigenic. Similar cells observed
in cultures prepared 90-91 days p.i. appear
to be lost on sub-culturing. These cells were
not seen when cultures were initiated at still
earlier times (60, 34-35, 5, 3, 2 days p.i.).
However it has been shown that cultures
prepared 2 days p.i. yield cells which are
tumourigenic on prolonged culturing. These
results provide a framework for further
analysis ofthe latent period and more detailed
studies are in progress.
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FIBRINOLYTIC ACTIVITY ASSOCI-
ATED WITH RAT BRAIN CELLS
EXPOSED TRANSPLACENTALLY TO
THE CARCINOGEN ETHYLNITRO-
SOUREA. T. A. HINCE and J. P. ROSCOE,
Department of Cell Pathology, School ofPatho-
logy, Middlesex Hospital Medical School.
An increased fibrinolytic activity of
tumour and transformed cells, as a result of
increased amounts of plasminogen activator,
has been proposed as another marker for
transformed cells (Jones et al. (1976) Cancer
Res., 36, 2863). In this study we have investi-
gated the fibrinolytic activity of cell lines
derived from cerebral gliomas of the rat brain
and cultures derived from the brains of rats
after their transplacental exposure to the
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carcinogen ethylnitrosourea (ENU) using
an in vivo/in vitro system (Roscoe and Claisse,
1976, Nature, Lond., 262, 314). Using a fibrin-
overlay method (Jones et al., 1975, Cell, 5,
323) we have demonstrated that cell lines
derived from a cerebral glioma and from rat
brains 111-112 days after their exposure to
the carcinogen show a very high level of
fibrinolytic activity. In contrast, control cells
and cultures derived from the brains of
animals exposed to buffer alone show low
levels of activity. A detailed study of the
relationship between fibrinolytic activity,
measured as the percentage of total colonies
giving lysis, and cell colony size indicated
that there was a marked difference between
transformed and control cells. Transformed
cells showed a rapid rise in fibrinolytic
activity with increasing colony size and
reached a plateau level >70%0 at colony
sizes of below 70 cells/colony; wihereas con-
trol cells showed a linear increase with
colony size and much reduced levels of
activity: <30%0 at larger colony sizes,
>130 cells-colony. Thus in this system an
increased amount of fibrinolytic activity is
associated with malignant transformation.
SV40-3T3 CELL PLASMINOGEN ACTI-
VATOR-MEDIATED INITIATION OF
MITOSIS IN QUIESCENT 3T3 CELLS.
P. WHUR, M. GORDON, D. C. WILLIAMS, C.
URQUHART and E. WRIGHT, Marie Curie
Foundation, Oxted, Surrey and Imperial
College, London and Royal Free Hospital,
Medical School, Londont.
The number of dividing cells ill a popula-
tion of quiescent 3T3 cells in low serum
increases, significantly in the presence of
SV40-3T3 cells and added plasminogen. This
effect is attributable to plasminogen activa-
tion (Whur et al. (1976) Nature, Lond., 260,
709). The effect of plasminogen activation on
mitosis decreases as serum stimulation
becomes optimal, suggesting that the former
may potentiate the latter. Scanning electron
micrographs show that plasminogen activa-
tion causes fissures to open between previously
confluent 3T3 cells; thus the diffusion boun-
dary layer may become disrupted, leading to
a reinitiation of mitosis by serum growth
factors. This mechanism may also operate
in vivo. Tumour cells would initiate a local
inflammatory response with consequenit leak-
age of serum; the plasminogen would then be
locally activated by the tumour cells which
*Would then divide at a faster rate.
CONTROL OF HAEMOPOIETIC
STEM-CELL POPULATIONS. E. G.
WRIGHT, Paterson Laboratories, Christie Hos-
pital and Holt Radium Institute, Manchester.
(Introduced by R. Schofield).
Haemopoietic cells are derived from com-
mon pluripotential spleen-colony-forming
stem cells (CFU-S). The majority of these
stem cells, in the normal steady state, are
not proliferating, but can be stimulated into
cell cycle by a decrease in their population
size. The nature of CFU-S proliferation con-
trol is not known. There is, however, evidence
that it is "local" rather than humoral. The
presence of proliferating and non-proliferat-
ing stem cells in, respectively, the bone mar-
row and spleens of phenylhydrazine (PHZ)-
treated mice (Rencrieca et al. (1970) Blood,
36, 764) has afforded the opportunity to
investigate the presence and role of local
factors responsible for the control of CFU-S
proliferation. This has been done by measur-
ing the proliferative activity of femoral and
splenic CFU-S resulting from the addition of
radiation-killed splenic or bone-marrow cell
populations. When bone-marrow cells from
PHZ-treated mice are incubated with irradi-
ated spleen cells taken from the same mice,
there is a marked fall in the proportion of
femoral CFU-S in DNA synthesis. In the
converse experiments, rapid triggering of
splenic CFU-S is achieved. Changes in
CFU-S proliferation have also been demon-
strated in other situations, where cell popula-
tions containing proliferating and non-
proliferating CFU-S are mixed. It is not,
therefore, a phenomenon specifically related
to the PHZ-treated mouse. The effects on
the proliferative activity of CFU-S resulting
from the incubation of haemopoietic cells
with irradiated cell populations suggest that
some part or parts of these populations con-
tain material capable of altering the rate of
stem-cell proliferation. It seems probable
that these findings represent some aspect
ofthe local physiological CFU-S proliferation-
control process.
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THE SPECIFIC STAINING OF
SUGARS IN THE HISTOCHEMICAL
ANALYSIS OF BONE MARROW
AND THE MYELOID LEUKAEMIAS.
R. W. STODDART, W. JACOBSON and R. D.
COLLINS, Strangeways Research Laboratory,
Cambridge. and Department of Pathology,
Vanderbilt University, Nashville, Tennessee,
U.S.A.
In many glycoproteins of cellular surfaces,
mannosyl residues lie in the "cores" of the
oligosaccharides, while sialic acid is always at
the non-reducing (exterior) terminals. Galac-
tosyl groups are usually either terminal or
sub-terminal to sialic acid. Fluorescent-
labelled concanavalin A (FL-ConA) can be
used to stain for a-mannosyl (or a-glucosyl)
groups; the similar derivatives of Ricinus
communis haemagglutin (FL-RCA) and of
aprotinin (FLA) stain for /-galactosyl groups
and sialyl groups respectively. Fresh smears,
or paraffin sections of methanol-fixed bone
marrow were used. Myeloblasts, myelocytes
and leucocytes showed staining of their
surfaces, cytoplasm and nuclear membranes
with all three stains. Granules in eosinophils
and basophils stained in each case, but those
of neutrophils bound only FL-ConA. In
megakaryocytes, there was intense cyto-
plasmic staining with FL-RCA and FL-
ConA; the platelets stained strongly with
FLA, FL-RCA and FL-ConA. Staining of
chromatin was seen in several cell types, but
was most intense (with each stain) in late
erythroblasts. In all malignant cells of the
myeloid series there was a general reduction of
staining with FLA and an increased binding
of FL-ConA at the plasmalemma.
ABNORMAL SACCHARIDES OF
HUMAN LYMPHOID LEUKAEMIAS
AND ALLIED LYMPHOMAS. W.
JACOBSON, R. W. STODDART and R. D. COL-
LINS, Strangeways Research Laboratory, Cam-
bridge, and Department of Pathology, Vander-
bilt University, Nashville, Tennessee, U.S.A.
Fluorescent-labelled lectins and aprotinin
have been used to study the defects in the
cell surface and intracellular saccharides of a
range of reticuloses. Materials were fixed in
anhydrous methanol and used for paraffin
sections, or were freshly prepared as spreads.
Autofluorescence was eliminated by a short-
treatment with osmium tetroxide, before
staining. Normal monocytes showed weak,
uniform staining for sialic acid and little
staining for other sugars. Malignant mono-
cytes stained weakly and irregularly for
surface sialic acid and showed very little stain
for galactose or mannose; some appeared to
show caps. In acute lymphoblastic (human
and murine) and chronic lymphocytic leuk-
aemias the malignant cells showed much less
staining for sialic acid than their normal coun-
terparts, both at the plasmalemma and nu-
clear membranes. Staining for mannose was
unaltered. There were no differences between
B and T lymphocytes. The malignant cells of
nodular and thymic lymphomas gave a
similar result. In all types of Hodgkin's
disease, the neoplastic lymphocytes were
characterized as showing a reduction in
sialic acid and in sub-terminal galactosyl
groups; Reed-Sternberg cells were weakly
stained for all sugars. Related, but rather
more complex abnormalities were seen in
myeloma, Waldenstrdm's macroglobulin-
aemia and leukaemic reticuloendotheliosis.
AN ABNORMAL SURFACE PROTEIN
OFTUMOUR CELLS. R. W. STODDART and
M. R. PRICE, Strangeways Research Labora-
tory, Cambridge, and Cancer Research Cam-
paign Laboratories, University of Nottingham.
Investigations of a membrane-bound pro-
tein of pI 4 00, which is present in the plasma
membranes of hepatomas and mammary
carcinomas of the rat, have been extended
to determine its subcellular location, its
relation to the pathology of the tumours, its
chemistry and its occurrence in other species.
lodination has shown that the protein is
accessible at the surface of hepatoma cells.
Traces of a similar protein are present in the
nuclear membranes of normal hepatocytes
and are greatly elevated in malignancy. In
regenerating liver it is maximally elevated
at Day 3, but it is far below the level in
tumour cells, and does not occur at the plas-
malemma. In human, canine, feline, murine
and porcine tumours, similar proteins have
been found. Foetal tissues (rat and human)
contain related proteins of lower pI. The
levels of the protein are not related to the
histological class of tumour, its invasiveness
or antigenicity, its degree of vascularity or
the extent of lymphocytic infiltration. There
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is evidence for its being a glycoprotein. Its
appearance during carcinogenesis has been
studied.
THE SYNTHESIS OF co-LACTAL-
BUMIN BY HUMAN MAMMARY
CARCINOMAS. K. L. WOODS, D. H. COVE,
A. HOWELL and D. A. HEATH, Department of
Medicine, University ofBirmingham.
a-Lactalbumin is the major whey protein
of human milk. Using a sensitive radio-
immunoassay we have sought evidence for
the synthesis of this protein by human mam-
mary carcinomas. The cytosol fraction 14/38
carcinomas contained measurable o-lactal-
bumin. The presence of a-lactalbumin was
closely associated wNith the presence of
oestrogen receptor, and the concentrations
of ox-lactalbumin and of oestrogen receptor
showed a linear correlation. Serum levels of
o-lactalbumin were studied in 50 patients
wvith breast cancer and compared with those
ofhealthy control subjects. In normal women,
the proportion having detectable circulating
A-lactalbumin varied from about 80O/ in
young adults to about 200/' in post-meno-
pausal subjects. At all ages the level was
generally below 10 ng/ml. The breast-cancer
patients showed the same proportion and
range of detectable serum levels as age-
matched controls. Serum ox-lactalbumin wNas
measured prospectively in 100 patients
with a variety of breast conditions. Although
marked differences were found between
patients with benign and malignant breast
diseases, these were entirely due to the
differeing age structures of the two groups.
It is concluded that although synthesis of
o-lactalbumin occurs in about a third of
human breast carcinomas, assay of this
protein in blood is unlikely to help in the
diagnosis or management of breast cancer.
However, the presence of o-lactalbumin in
tumour cytosol is related to the oestrogen-
receptor content and may indicate the
tumour's hormone responsiveness.
A COMPARATIVE STUDY OF TWO
TUMOUR MARKERS IN BREAST
CANCER. F. SEARLE, K. D. BAGSHAWE and
G. GOKA, Department of Medical Oncology,
Charing Cross Hospital, London.
Marked serum elevations of carcino-
embryonic antigen (Chu and Nemoto (1973)
J. natn. Cancer Inst., 51, 1119), casein
(Hendrick and Franchimont (1974) Europ.
J. Cancer, 10, 725), and various less specific
biochemical markers (Coombes et al. (1977)
Lancet, i, 132) have been observed in meta-
static breast cancer, but it is necessary to
establish wA-hether these markers have a useful
role in clinical practice. The serial assay of
serum carcinoembyronic antigen in patients
undergoing treatment suggests that liver
and bone metastases will cause an elevation
more readily than does local recurrence.
Serum casein is elevated in a proportion of
patients with primary breast cancer (240')
of varying histological grade. In a small
series of patients wN-ho have undergone
bilateral mastectomythere is a lowerincidence
of casein positivity than in a larger series
after bilateral mastectomy. Preliminary
studies indicate that neither marker is
elevated in direct response to certain cyto-
toxic drug regimens.
THE COMPETITIVE NATURE OF
06-METHYLGUANINE MISCODING
DURING DNA SYNTHESIS. P. J. Abbott
and R. Saffhill, Paterson Laboratories, Christie
Hospital and Holt Radium Institute, Man-
chester.
The synthetic DNA-like polynucleotide
poly(dC-dG) has been methylated in vitro
with either dimethyl sulphate (DMS) or the
potent carcinogen N-methyl-N-nitrosourea
(MNU) and the levels of the various methyla-
tion products determined. Treatment with
either DMS or MNU resulted in the formation
of 3-methylguanine, 7-methylguanine and
3-methylcytosine whilst MNU-methylation
also produced 06-methylguanine and phos-
photriesters. The methylated polymers were
then used as templates for E. coli DNA
polymerase I in an in vitro assay and the
amounts of complementary and non-com-
plementary base incorporation measured in
concurrent assays. The DMS-methylated
polymer did not produce any mis-incorpora-
tion, indicating that the products of DMS-
methylation do not miscode. The MNU-
methylated polymer directed the incorpora-
tion of thymine but not of adenine. Presum-
ably this was due to the presence of o6-
methylguanine (a promutagenic base) in the
template. The thymine incorporation, how-
ever, varied with the ratio of the 5'-triphos-
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phates of deoxythymidine and deoxycytidine
in the assay, and wtas less than the o6-
methylguanine content of the template.
These results indicate that 06-methylguanine
is capable ofmiscoding during DNA synthesis
but the miscoding competes with the normal
incorporation of cytidine. 3-Methylcytidine,
which has been shown to lead to mis-incor-
poration wsith RNA polymerase (Ludlum
(1971) Biochirn. biophys. Acta, 247, 412)
does not miscode in our DNA polymerase I
system. The competitive nature of the 06-
methylguanine miscoding is of interest:
presumably it could be another of the many
factors determining the tissue specificity of
methylating carcinogens.
CORRECTION OF CHANGES IN
LIVER METABOLITES OF MICE
FOLLOWING CURATIVE TUMOUR
RESECTION. K. C. CALMAN, R. A. Mc-
ALLISTER and M. SOUKOP, Department of
Clinical Oncology, Gartnavel General Hospital,
Glasgow and Department of Surgery, We8tern
Infirmary, Glasgow.
Earlier work (Calman and McAllister (1975)
Br. J. Surg., 62, 161; Br. J. Cancer, 32, 247,
BACR presentation, Swansea, 31 March
1976), demonstrated in the non-involved
liver of mice bearing a TLX-5 lymphoma,
C3H mammary tumour, or Sarcoma 180,
significant alterations in metabolites, in
particular coenzyme A and citrate. Extension
of this work has been conducted with the
C3H mammary tumour and TLX-5 lym-
phoma systems. With the C3H mammary
tumour, significant depressions (P < 0.001)
of CoA content of liver occurred in the
presence of a primary tumour (mean weight
0.5 g). Curative resection of this small
tumour caused a return of CoA levels to the
normal range. In a second experiment,
inoculation of a cell-free supernatant of the
TLX-5 lymphoma into normal mice mirrored
the metabolic alterations, i.e. fall in CoA
and a rise in citrate levels which had been seen
in tumour-bearing animals. Interestingly,
similar increases in spleen weight and con-
comitant involution of thymus were seen in
both groups of mice. In conclusion, further
support is given to the suggestion that these
changes in liver metabolites are directly
related to the presence of a tumour product.
However, the nature ofthis is as yetunknown.
COMPETITIVE BINDING OF CYCLO-
PHOSPHAMIDE AND ITS META-
BOLITES WITH CYCLIC-AMP-BIND-
ING PROTEINS M. J. TISDALE, Depart-
ment of Biochemistry, St. Thomass Hospital
Medical School, London.
There is a similarity in the biochemical
effects of cyclophosphamide and cyclic AMP.
Both produce hyperglycemia and cause an
increase in tyrosine transamminase, ornithine
decarboxylase and alkaline phosphatase acti-
vity. This suggests that cyclophosphamide
or its metabolites may interact with cyclic-
AMP-specific proteins. A 4-hydroxyl substi-
tuent in the 1,3,2-oxazaphosphorine ring is
required for inhibition of AMP binding to
both AMP phosphodiesterase and to the
regulatory subunit ofthe AMP-protein kinase
holoenzyme. Binding to the latter causes an
activation of the kinase and results in a dis-
sociation into regulatory and catalytic sub-
units. The inhibitor constant, Ki, for the
inhibition of AMP binding to the protein
kinase holoenzyme (0-19 mM) correlates well
with that for inhibition of the low Km form
ofthe phosphodiesterase. In both cases inhibi-
tion is of the competitive type. Although the
Ki value for inhibition of phosphodiesterase
by 4-hydroxycyclophosphamide is much
higher than the ID50 value, it causes a time-
dependent inactivation of the enzyme prob-
ably due to the release of N,N-di(2-chloro-
ethyl)phosphorodiamidic acid. Thus the low
affinity binding to phosphodiesterase could
act as a highly efficient mechanism for
enzyme inhibition. Although 4-ketocyclo-
phosphamide resembles 4-hydroxycyclophos-
phamide in electron-donating properties, it is
inactive with respect to binding to AMP-
specific sites. This probably results from the
difference in conformation of the rings of
these two compounds.
HYDROXYUREA "SUICIDE" STUDIES
ON CLONOGENIC CELLS OF THE
LEWIS LUNG CARCINOMA. A. E.
BATEMAN and G. G. STEEL, Division of
Biophysics, Institute of Cancer Research,
Sutton, Surrey.
Studies on cells synchronized in vitro have
demonstrated that the level of killing by
cytotoxic agents varies with the position of
the cells in the cell cycle. We present results
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on Lewis lung tumour clonogenic cells treated
in vivo, which show variations in survival
between S-phase and non-S-phase cells after
treatment with cytotoxic drugs. Thehydroxy-
urea suicide technique is used in vitro to
measure the proportion of clonogenic cells
in S-phase both for untreated cells and for
cells treated in vivo with cyclophosphamide
(CY) 1-(2-chloroethyl)-3-cyclohexyl-1-nitro-
sourea (CCNU) and irradiation. Forty-five
per cent of untreated clonogenic cells are in
S phase, as thus determined, whereas up to
70% of cells surviving CY and 85% of cells
surviving CCNU are in S. We conclude that
S-phase cells are more resistant than G1 or
G2 cells to these agents.
O-PHOSPHATE AND O-GLUCURO-
NIDE DERIVATIVES OF p-HYDRO-
XYANILINE MUSTARD: POTENTIAL
LATENTANTINEOPLASTICAGENTS.
P. WORKMAN* and J. A. DOUBLE, Depart-
ment of Cancer Research, University ofLeeds.
The 0-phosphate (AMPh) and 0-glucuro-
nide (AMG1) esters of p-hydroxyaniline
mustard (AMOH) were synthesised as poten-
tial selective agents for tumours containing
high levels of phosphatase and ,B-glucuroni-
dase, respectively. Specificity would be
dependent upon their localized conversion
to the potently cytotoxic AMOH catalysed
by tumour enzymes (Bukhari, Everett and
Ross (1971) Biochem. Pharnwac, 21, 963).
Partitioning studies showed that AMPh and
AMG1 were more polar than AMOH, due to
the presence of the ionized phosphate and
glucuronate moieties. The chemical half-
life (t1/2) of the mustard group of AMG1 in
aqueous solution (21 min) was longer than
that of AMOH (12 min); AMPh (tl/2==
13 min) was, however, as reactive as AMOH.
Enzyme kinetic studies have shown that
AMPh was hydrolysed more rapidly by acid
and alkaline phosphatases of mouse bone
marrow and small intestinal mucosa than by
the corresponding enzymes of transplantable
mouse tumours. Km values for normal and
neoplastic mouse tissues were similar. In
addition, AMPh was rapidly hydrolysed by
blood serum phosphatases. It was thus
unlikely that AMPh would be a selective
* Present address: MRC Clinical Oncology and
Radiotherapeutics Unit, The Medical School, Hills
Road, Cambridge.
antineoplastic agent. AMPh was, however,
more effective than AMOH against trans-
plantable tumours containing comparatively
high levels ofalkaline phosphatase. Apositive
correlation was observed between sensitivity
to aniline mustard (AM) and tumour ,B-
glucuronidaselevels, thus confirming previous
findings (Connors and Whisson (1966) Nature,
Lond., 210, 866). Although sensitivity to
AMG1 also correlated with tumour/-glucuro-
nidase activities this agent was less effective
than AM.
VIABLE TUMOUR REGIONS INAC-
CESSIBLE TO CHEMOTHERAPEUTIC
AGENTS AND A POSSIBLE NEW
STRATEGY FOR INACTIVATING
THEM. R. J. GOLDACRE, Chester Beatty
Research Institute, London.
Studies with systemic dyes haveshownthat
advanced tumours have large ischaemic
zones frequently containingsubstantial quan-
tities of living tumour cells. The question is:
are these cells responsible for tumour recur-
rence after chemotherapy?
Transplantations were made from both the
vascular and ischaemic zones (as marked out
by systemic dyes) of advanced (9-day)
Walker tumours after the rats bearing the
tumours had been given chemotherapy by
melaphalan at various doses. As the dose
increased, the percentage of takes from the
vascular zone fell from 100% to zero, whereas
the takes from the ischaemic zone remained
fairly constant at about 20%.
This shows clearly that chemotherapeutic
agents do not reach all stem cells in advanced
tumours. Modifying the chemical structure
ofdrugs is unlikely to affect the lack oftrans-
port in ischaemic regions, and a new strategy
is required for dealing with the inaccessible
cells. The following experiments suggest a
possible solution.
Advanced Walker tumours after chemo-
therapy nearly all recurred when left in situ,
but when transplanted whole to new hosts,
no tumours grew. However, when the ischae-
mic zone was transplanted after removing
the vascular (killed) shell, many tumours
grew. Therefore, the stem cells in the ischae-
mic zone are unable to penetrate the killed
(formerly vascular) shell which has no blood
supply since its vessels were cut for the
transplantation.
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A comparable impenetrable shell was
generated in situ by a combination of sero-
tonin, which selectively shuts down tumour
blood supply, followed after 4 hbymelphalan.
The serotonin doubled the cure rate, and
trebled the survival rate (half life after treat-
ment) of rats bearing advanced Walker
tumours.
SPECIFICITY OF IgG ANTIBODIES
IN HODGKIN'S DISEASE. D. B. JONES,
E. V. ELLIOTT,* S. V. PAYNE and D. H.
WRIGHT, University Department of Pathology
and *Tenorvus Laboratory, Southampton.
Hodgkin's spleen tissue cultured for 72 h
in the presence of 14C-leucine shows increased
incorporation into secreted IgG measured
by a specific immunoprecipitation technique,
when compared with controls. IgG prepared
by affinity chromatography from the
culture supernatant of one patient with a
high synthesis rate was capable of binding
to human peripheral blood lymphocytes.
Angibody capable of binding to human lym-
phocytes was also present in the serum of
this patient and could be typed as IgG K;A.
In a further series of pretreatment Hodgkin's
sera screened by lodinated-protein-A, 20% of
patients showed IgG binding to human
lymphocytes. However, when further exam-
ined on peripheral lymphocyte subpopula-
tions and lymphoid cell lines, the specificity
of this antibody was not restricted to T cells
as suggested by del Giaco et al. (1976)
Biomedicine, 25, 79). Further, when tested
in a 51Cr-release assay, none of these sera
were able to kill lymphocytes in the presence
of complement; preliminary results suggest
this lack of cytotoxicity may be due to the
subclass of IgG present. Binding sera fre-
quently showed other tissue autoantibody
specificities and this suggests that the anti-
lymphocyte-antibody present may be an
additional disease-associated autoantibody
rather than an aetiologic factor associated
with a lymphocyte war.
G. S. del Giaco et al. (1976). Anti-lympho-
cyte-antibodies in Systemic Lupus Erythe-
matosus and in Hodgkin's Disease: A Com-
parison by Immunofluorescence.
IMMUNOFLUORESCENT STUDIES
OF HUMAN-LUNG-CANCER ANTI-
27
SERA. C. E. Newman, C. H. J. Ford and
H. J. STOKES, University Department ofSur-
gery, Queen Elizabeth Hospital, Birmingham;
G. J. O'NEILL, G. D. Searle Research Labora-
tories, High Wycombe; and R. A. THOMSON,
Regional Immunology Laboratory, East Bir-
mingham Hospital, Birmingham.
Thirty xenoantisera have been prepared
in goats against lung cancers. Haemaglutinat-
ing, haemolytic and lymphocytotoxic anti-
bodies were removed by sequential absorp-
tions with human spleens, and the immuno-
globulin (Ig) fractions precipitated. Each
absorbed Ig was examined for selective
uptake by the tumour cells against which it
was prepared. The test system is an indirect
immunofluoreseent (IF) test using cryostat-
cut sections from specimens of the original
tumour, snap frozen and stored in liquid N2,
and a rabbit anti-goat gammaglobulin fluores-
cein-isothiocyanate conjugate. Every Ig
showed selective localization by the original
tumour cells. Titres ranged from neat to 1/32.
In most cases, non-specific fluorescence was
observed against connective tissue and
endothelial cells. This was always similar to
that seen with an Ig prepared in the same way
against a mycosis fungoides tumour. Signifi-
cant selective localization of this Ig by lung
tumour cells was not observed. Absorbed
Igs showed positive tumour-cell fluorescence
when examined for selective localisation by
lung tumours of the same and different
histological types, suggesting a surprisingly
high cross-reactivity. A xenoantiserum pre-
pared against cultured oat-cell carcinoma
cells had high titres of haemolytic (1/96)
haemagglutinating (1/512) and lymphocyto-
toxic (1/3072) antibodies which were removed
by absorption. After absorption, the IF
titre against lung tumour cells was 1/1200.
The fractionated Ig has an IF titre of 1/80
to 1/160. This reagent has been carefully
assessed against a panel of 8 lung cancer
sections comprising 2 of each of the histolo-
gical groups viz. oat-cell, anaplastic, adeno
and squamous. In 7/8, the tumour-cell
concentration of IF-detected antibody is
apparent at titres of1/80 to 1/160. The control
Ig (mycosis fungoides) does not demonstrate
this tumour-cell concentration. This evidence
suggests the selective localization of tumour-
cell antigens on human lung cancer cells.
These may be tumour-specific, tumour-associ-
ated or even normal cellular antigens selec-
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tively cOncentrated in the tumour-cell
membrane.
THE DEMONSTRATION OF
DEPRESSED LEVELS OF T LYMPHO-
CYTES IN BREAST CANCER
PATIENTS IS DEPENDENT ON THE
METHOD USED. R. H. WHITEHEAD,
G. P. ROBERTS, J. THATCHER and L. E.
HUGHES, University Department of Surgery,
Welsh National School of Mkedicine.
There are a number of conflicting reports
on the proportion of E-rosetting cells (T
lymphocytes) detectable in patients with
breast cancer. However, different rosetting
techniques have been used in each study, and
it was felt that this might be the cause of the
differing results obtained. We have therefore
compared three standard rosetting tech-
niques:
(a) short incubation period of 1I h at
4°C in PBS
(b) overnight incubation at 4°C in PBS
and
(c) 1-h incubation at 4°C in 5% FCS.
In addition, the effect of methodology on
cancer-serum-induced inhibition of E-rosette
formation by normal lymphocytes has been
studied. It was found that when the number
of E-rosetting cells was determined using
incubation at 4°C for 1 I h, levels in women
with breast cancer and an age-matched
control group were both significantly lower
than the levels obtained for a young control
group. There was no difference between the
3 groups when rosetting was performed in
5% FCS or by overnight incubation, as the
proportion of E-rosetting cells was then
higher in the first two groups. Inhibition of
E-rosette formation by incubating normal
lymphocytes in breast cancer serum could
be demonstrated using a short incubation
period (11 h) but not after overnight incuba-
tion or after incubating the treated lympho-
cytes in saline overnight at 4°C before
rosetting. These findings explain the previous
conflicting results, and suggest the presence
of a factor(s) on the surface of T lymphocytes
of cancer patients and in the sera of these
patients which bindsreversibly to the lympho-
cyte surface and in some way masks the
E-receptor site.
A TWO-STAGE ASSAY FOR
TUMOUR-DIRECTED CELL-MEDIAT-
ED IMMUNITY. A. J. COCHRAN, R. M.
MACKIE, L. J. OGG, A. M. JACKSON, C. E.
Ross and G. TODD, University Departments
of Pathology and Dermatology, The Western
Infirmary, Glasgow.
In an attempt to overcome problems of the
one-stage leucocyte migration inhibition assay
we are investigating a two-stage test. In
Stage I Ficoll-Hypaque (FH) separated
mononuclear cells areincubated withformalin-
fixed cells (FC) of the appropriate tumour
type, of other tumour types and with
formalinized normal cells. After 24 h the
migration-inhibiting activity of the various
supernatants is assessed relative to the super-
natant ofFH cells incubated in the absence of
formalinized cells. The indicator-cell popula-
tion is gravity-sedimented peripheral blood
leucocytes from a normal individual. Active
supernatants resulted more often from co-
cultre of melanoma leucocytes (ML) with
melanoma cells (17/39-44%) than from
cultures of ML with other types of cells
(6/41-150%). Active supernatants infrequently
resulted from culture of normal FH cells
with FC (control FH cells/melanoma FC,
1/30 (3%o) control FH cells/other FC, 4/22
(180 ). Active supernatants were most fre-
quent with FH cells from Stage II melanoma
patients (Stage I, 1/6 (17%), Stage II,
14/25 (56%) and Stage III, 2/8 (25%).
In combinations of ML with melanoma FC
the reaction frequency increased with the
number of FC preparations tested. This was
not seen with combinations of ML and other
FC or control leucocyte cultures with mela-
noma or other FC. The direct and two-stage
assays were concordant in about 700% of
concurrent tests.
A CONTROLLED TRIAL OF ACTIVE
IMMUNOTHERAPY IN THE MAN-
AGEMENT OF STAGE IIB MALIG-
NANT MELANOMA. M. B. MCILLMURRAY,
M. J. EMBLETON, W. G. REEVES, M. J. S.
LANGMAN and M. DEANE,* Department of
Therapeutics, Cancer Research Campaign
Laboratories, Department of Immunology,
University of Nottingham and *the Plastic
Unit, City Hospital, Nottingham.
Within two years of operation about three-
quarters of all patients with malignant
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Recurrence rate
Vaccinate(c Control
3 mouiths
6 months
12 months
3/8
4/8
4/8
melanoma who have regional nodes involved
(Stage IIb) will have obvious recurrences
and more than half of these will have died
(Lane, N., Lattes, R. and Malm, J. (1958)
Cancer, 11, 1025. Inmprovements in results
are therefore only likely to ensue if some
other treatment can be added to excision.
Animal studies indicate that host resistance
to transplantable tumours is enhanced when
BCG and tumour-cell vaccines are given
together as contact immunotherapy, provided
that the tumour load is small, suggesting that
such a combination mav be a more effective
immunostimulant than either given alone
(Bast, R. C. et al. (1974) New Engl. J. Med.
290, 1413) Fifteen patients with Stage IIb
malignant melanoma were randomly allocated
to either a treatment group in which they
received a vaccine (3 x 107 live BCG and
5 X 107 autologous irradiated tumour cells)
or a control group who received no further
treatment after surgical eradication of their
disease. The recurrence and death rates in
the two groups one year later are shown in
the table.
These results suggest that active immuno-
therapy may cause tumour enhancement in
some patients with malignant melanoma, and
that claims of benefit from uncontrolled and
unrandomized studies should not be readily
accepted.
IMMUNOLOGICAL MONITORING
OF PATIENTS UNDERGOING ACTIVE
IMMUNOTHERAPY FOR STAGE IIB
MALIGNANT MELANOMA. M. J.
EMBLETON, M. B. MCILLMURRAY, J. H.
RANSOM and W. G. REEVES, Cancer Research
Campaign Laboratories and Departments of
Therapeutics and Immunology, University of
Nottingham.
Fifteen patients with Stage IIB malignant
melanoma were allocated to a group receiving
a vaccine (3 x 107 live BCG and 5 x 107
autologous irradiated tumour cells) following
tumour resection, and a control group who
were given no further treatment. All patients
0/7
2/7
4/6
D)eath rate
a- a
Vaccinated Control
2/8
3/8
4/8
0/7
0/7
0/6
wNere monitored immunologically before treat-
ment, and at 3, 6 and 12 months after treat-
ment, in order to look for changes in immune
function wvhich might correlate with their
clinical course, and thus provide a test with
prognostic significance. Immunocompetence
of patients was assessed by skin tests, using
the recall antigens PPD and Varidase,
measurement of blood components, and by
lymphocyte transformation ini vitro wvith
various agents. Attempts wvere made to
evaluate tumour-directed immunity using
in vitro tests for both leucocyte-mediated
and antibody-mediated activity against mela-
noma extracts or cultured cells. Th-ere wvas a
trend towAards earlier tumour recurrences
in patients wvith poor skin reactivity to PPD
and Varidase at the beginning of treatment.
The in vitro measurements fluctuatedthrough-
out the time course for each patient, and
none revealed any significant differences
between patients with good or bad prognosis,
or between vaccinated and control patients.
It is concluded that in vitro monitoring using
present techniques is of no practical value in
prognosis of malignant melanoma.
RESULTS, FOR 27 MONTHS OF
FOLLOW-UP, OF A STRATIFIED
RANDOMIZED TRIAL OF INTRA-
DERMAL BCG IN ADDITION TO CON-
VENTIONAL TREATMENT IN
PATIENTS WITH LUNG CANCER.
H. M. ANTHONY, K. E. MADSEN, M. K.
MASON and G. H. TEMPLEMAN, University
Department of Immunology, Leeds General
Infirmary and Killingbeck Hospital, Leeds.
Random allocation of 75 men with con-
firmed bronchial carcinoma to BCG (0-1 ml
Glaxo BCG i.d. monthly to 6 months) or
control within a stratification system based
on conventional therapy and other prognostic
factors, showed no significant prolongation of
life by BCG, by sequential analysis of 23
pairs or by life table analysis (computer
program kindly loaned by Dr P. G. Smith of
Oxford). The latter analysis shoNwed signifi-
cant prolongation of survival in "acceptable
409B.A.C.R. 18TH ANNUAL GENERAL MEETING
clinical" condition (P - 0.0049) or good
general condition (P -- 0-0112) for BCG-
treated radical radiotherapy patients. For
almost all groups, BCG had greater effect on
prolongation of "acceptable clinical" or good
general condition than on survival to death.
BCG also reduced weight loss. These effects
could be due to increase in T-lymphocyte
proportion by BCG (Anthony et al. (1975)
Clin. exp. Immunol., 20, 40) or to stimulation
of macrophages. In patients with squamous
carcinoma, peripheral blood lymphocytes
and monocytes directly correlated with
length of survival (P < 0-02, P < 0.04) in
keeping with partial immune control. For
oat cell carcinoma, lymphocyte numbers
inversely correlated with "Survival" (P <
0.04) as did the trend with monocyte number
(P < 0.03) suggesting resistance to immune
cytolysis in oat cell carcinomas and a stimu-
lating effect for immune attack.
C-TYPE RNA TUMOUR VIRUSES:
ISOLATION AND CHARACTERIZA-
TION OF A COMPLETE DNA COPY
OF THE ERYTHROID-SPECIFIC
FRIEND VIRUS GENOME. I. B. PRAG-
NELL, W. OSTERTAG* and J. PAUL, Beatson
Institute for Cancer Research, Wolfson
Laboratory for Molecular Pathology, Glasgow
and *Max Planck Institut fur Exp. Med.,
G&ttingen, West Germany.
Friend virus (FV) is a C-type RNA
tumour virus which induces an erythro-
leukaemia in susceptible mice, and the trans-
formed erythroid cells can be maintained in
tissue culture (Friend et al. (1966) Nat. Canc.
Monogr., 22, 505). These cells can be stimu-
lated to differentiate along the erythroid
pathway by addition of aprotonic solvents
such asdimethylsulphoxide(Friendetal. (1971)
Proc.Nat. Acad.Sci., U.S.A.,68, 378; Ostertag
et al. (1972) Nature, New Biol., 243, 203). We
have synthesized and characterized a viral
3H-labelled complementary DNA (eDNA)
derived from the Friend virus genome.
Hybridization analysis has shown that:
(a) The FV eDNA is a full-lengthl copy of
the Friend virus genome.
(b) The base-sequence complexity of the
viral genome is 4 x 106 daltons.
(c) There are 4-7 viral genes homologous to
the FV genome in normal (DBA/2)
mouse DNA and 10-12 viral genes per
haploid genome in DNA from the FV-
transformed Friend cell. A significant
minor proportion (20-300//) of the FV
eDNA probe anneals only to virus
related sequences in the transformed-
cell DNA, indicating that additional
FV-related sequences are integrated
in the transformed-cell DNA. The
Friend virus consists of a helper
lymphatic leukaemia virus (LLV) and
the erythroid-specific defective spleen-
focus-forming virus (SFFV). We have
isolated by end-point dilution and
cloned a cell line producing only the
LLV component. The 70S RNA from
LLV can be used to remove the LLV
sequences from FV eDNA, resulting
in enrichment of the erythroid-specific
sequences and/or the sequences in-
volved in transformation of the target
cell.
CELL-MEDIATED RESPONSE TO
SIMIAN ONCORNAVIRUSES IN
WOMEN DURING PREGNANCY. L.
THIRY, S. SPRECHER-GOLDBERGER, M. Bos-
SENS and F. NEURAY, Institut Pasteur du
Brabant and Free University of Brussels.
(Introduced by F. J. Lejeune).
Baboon type-C virus and Mason-Pfizer
virus (MPV) were added to short term human
leucocyte cultures and induced a high level
of thymidine incorporation, due to virus
replication. Killed viruscs caused a limited
but significant level of thymidine incorpora-
tion in some leucocyte cultures, indicating
that some individuals possess lymphocytes
sensitized to antigens carried by one of the
viruses. Cells chronically infected with each
virus, or not infected, were treated with
mitomyein C; one type of infected culture
specifically stimulated some leucocyte cul-
tures, but responses to the infected cells
were not always associated with responses
to the corresponding virus. Because oncor-
navirus particles have been described in
placentas, lymphocyte responses to th-e
Baboon virus and to MPV were studied in
30 women at the end of pregnancy and in 37
non pregant women. Lymphocyte responses
to cells infected with either the Baboon
virus or with MPV were found in 36% and
2.60% of the pregnant and non-pregnant
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w8omen, respectively, and were most frequent
in -women with many gestations. The number
of responses to one of the two virus particles
was not different in pregnant and non-
pregnant women, but increased with the
number of gestations, since they were found
in 0% of gravida 0, in 16°/ of women with
1-4 gestations, and in 530o of women with
5-7 gestations. Antigens similar to those of
Baboon virus or MPV may be expressed
during gestations.
VSV PSEUDOTYPES PRODUCED IN
HUMAN MELANOMA CELL LINES.
N. VAN TIEGHEM, D. LITEANU, A. F. VERCAM-
MEN-GRANDJEAN, P. VANDENBUSSCHE, D.
DEKEGEL, L. BEAUMONT and F. J. LEJEUNE,
Universite Libre de Bruxelles, Institut Pasteur
du Brabant and Institut Bordet, Bruxelles.
Three human melanoma sublines w-ere
investigated for viral particles. Electron
microscope studies showed a high production
of melanosomes and viral particles budding
intothe cisternae oftheendoplasmic reticulum
in cells derived from a subcutaneous meta-
stasis (HM6B-A). This viral expression was
related to melanin expression, and could be
switched on or off by adding to, or subtract-
ing tyrosine from the culture media. When
infecting an amelanotic subline (HM6B-N),
provided by the same patient, with a VSV
thermolabile mutant (tl) there was produc-
tion of a VSV pseudotype (Zavada, J. (1972)
Nature, New Biol., 240, 124). The coat of
progeny VSV was modified: the thermolabile
virus had become thermostable. This cell
line did not show virus expression either
after the tyrosine test or after treatment
with halogenated pyrimidines (Lowy, D. R.,
Rowe, W. P., Teich, N. and Hartley, J. W.
(1971) Science, 174, 155). The amount of
VSV pseudotype particles was increased
2500 x in the presence of (5-JUdR). Reverse
transcriptase activity in the culture super-
natant was barely detectable. The VSV
pseudotypes could be neutralized by the
patient's serum. When treating another
amelanotic subline (HM6A) from the same
origin with DL-DOPA (8-0 x 10-5M/ml)
it was possible to detect a few virus-like
particles. Thermostable pseudotypes were
also obtained in the presence of this drug.
Thus, VSV pseudotype particles could be used
as a tool to detect one (or more) neutraliza-
tion antigens to one (or more) "putative"
human melanomaviruses.
CROSS-REACTIVITY OF ANTISERA
TO ONCOGENIC RNA VIRUS PRO-
TEINS WITH HUMAN LEUKAEMIA
CELLS. A. PILLAI,*, N. HOGGt and R. T. D.
OLIVER, *Imperial Cancer Research Fund,
Department of Medical Oncology, St Bartholo-
mew's Hospital, London, and tImperial Cancer
Research Fund, Tumour Immunology Unit,
University College, London.
Antisera raised in rabbits against PAGE-
separated proteins from disrupted Moloney
virus have been tested against a panel of
leukaemia cells from 17 patients w%Nith AML,
6 patients with ALL, 5 patients with CLL,
7 remission lymphocytes from 7 patients
with acute leukaemia and lymphocytes from
8 normal laboratory controls. A standard
microcytotoxicity assay writh absorbed wean-
ling rabbit serum as a complement source was
used. Reactivity was greatest in serum
against gp 79/80 (18/28 positive with from
12-80% cytotoxicity) and least with serum
against p30 (6/28 positive with from 10-50%
cytotoxicity). Intermediate reactivity was
observed with antisera to p15 (envelope),
p15 and p12. Reactivity against remission
lymphocytes was considerably less than
against leukaemia cells, although 3/15 cells
tested did show slight reactivity (12-42%).
Cross-absorption experiments with different
types of leukaemia cells suggest that the
determinants detected on ALL and CLL
cells are the same as on AML. Studies are in
progress, using the lysostrip technique, to
clarify the relationship of the determinants
detected by these sera to normal tissue
antigens, B2 microglobulin and HLA.
EFFECT OF HYPERTHERMIA ON
THE IMMUNOCOMPETENCE OF
NORMAL AND VX2 TUMOUR-BEAR-
ING RABBITS. S. A. SHAH and J. A.
DICKSON, Cancer Research Unit, University
Department of Clinical Biochemistry, Royal
Victoria Infirmary, Newcastle-upon-Tyne.
FolloNwing effective heat treatment of a
primary cancer in man and in animals,
tumour mnetastases also disappear wvith cure
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of the host. With the rabbit VX2 carcinoma,
heat applied locally to the tumour is more
effective than total-body heating, and it is
believed that, an altered response of the
animal's immune system may be involved
in this difference (Dickson (1976) Int. Syymp.
Cancer Therapy by Hyperthermia and Radia-
tion. Am. Coll. Radiology Press, Baltimore,
Md. p. 134). In the present study, 9/19 VX2
tumour (15-20 ml) bearing rabbits treated by
Local Radiofrequency Heating (LRFH, 47-
50°C/30 min), and 1/8 rabbits treated by
LRFH followved 8 days later by Total-body
Hyperthermia (TBH) at 42°C (1 h on each
of 3 successive days) wvere cured. Skin
response to challenge with Dinitrochloro-
benzene (DNCB) or tumour extracts, and
the anamnestic response to bovine serum
albumin (BSA) in tumour bearing rabbits
increased following LRFH with untreated
or (LRFH + TBH) treated rabbits. In vitro,
lymphocytes plus serum from cured animals
caused greater inhibition (30-650O)) oftumour
cells than lymphocytes plus serum from
untreated animals (20-300/o). In normal
rabbits, LRFH or TBH did not affect the
skin response to DNCB. The response to
BSA was reduced by up to 1/25 normal level
following LRFH and by up to 1/80 normal
level after TBH. The data support the
previous postulate that TBH suppresses the
immune system.
CELL-MEDIATED CYTOTOXICITY IN
TUMOUR-BEARING DOGS. G. R. BET-
TON, Oncology Unit, Department of Clinical
Veterinary Medicine, University of Cambridge.
Dogs bearing spontaneous neoplasms were
tested for peripheral blood lymphocyto-
toxicity using 51Cr-labelled allogeneic tumour
target cells. Where possible, sequential testing
was performed during the course of therapy.
Analysis of results obtaiiied with melanoma-,
osteosarcoma- and mammary-carcinoma-
bearer peripheral blood lymphocyte prepara-
tions tested against tumour target cells of the
same and different histological types shoved
no evidence for type specificity. Healthy
control donors also exhibited non-specific
cytotoxicity in a proportion of donors, that
was not significantly different from that
observed in tumour bearers. Sequential
testing oftumour bearers showed no consistent
responses to treatments such as i.v. BCG
immunotherapy, but dogs involved with
metastatic disease showed lower responses.
Responses of BCG-treated tumour bearers
were lower than those seen in healthy BCG-
treated controls. The use of autochthonous
tumour target cells was unsatisfactory, as
short-term cell cultures were resistant to
lysis in the 5-Cr-release assay when compared
with established allogeneic cell lines. The
non-specific effector cell rosetted with human
erythrocytes, a canine T-cell marker, but
carbonyl iron treatment also reduced non-
specific cytotoxicity in some cases. Certain
target cell lines, e.g. osteosarcoma, were
particularly sensitive to non-specific lysis.
Lymphocytotoxicity detected in the allo-
geneic 51Cr release assay was therefore not
directed at tumour specific antigens and was
present also in healthy controls. Spontaneous
canine neoplasms appeared to lack histolo-
gical-type-specific antigens capable of elicit-
ing a cell-mediated cytotoxic response in the
tumour-bearing host.
STUDIES ON THE MICROCYTO-
TOXICITY TEST: THE UPTAKE OF
AMINO ACIDS BUT NOT NUCLEO-
SIDES PROVIDES A DIRECT AND
QUANTITATIVE MEASURE OF
TARGET CELL SURVIVAL. R. C. REES
and C. G. BROOKS, Cancer Research Cam-
paign Laboratories, University of Nottingham.
Optimal labelling of tumour cells with
radionucleosides required that these precur-
sors be present at high concentration, because
many tumour-cell targets did not utilize
exogenous nucleoside efficiently when present
at low concentration. However, even using
relatively high concentrations of radio-
nucleoside, large discrepancies between radio-
nucleoside uptake and -cell survival assessed
by cell counting were often found. Analysis
revealed that two types of soluble factors
released by lymphoid cells were responsible
for the discrepancies.
(a)
(b)
Competitive inhibitors of nucleoside
uptake, removable by washing.
Factors which caused an irreversible
disruption of tumour cell nucleoside
metabolism without any apparent
effect on cell survival.
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In contrast to the severe problems encoun-
tered with radionucleosides, radio-labelled
amino acids were taken up equally avidly by
all tumour cells tested, and provided a direct
and precise measure of target-cell survival,
because neither competitive nor non-com-
petitive interference with amino-acid uptake
caused by lymphocytes or lymphocyte factors
was detectable. The use of the y-emitting
75Se-methionine as precursor permitted a
simple and rapid method of quantitating
target-cell survival in the microcytotoxicity
test.
SPONTANEOUS DEVELOPMENT OF
CYTOTOXIC ACTIVITY IN CUL-
TURES OF LYMPH NODE CELLS
FROM TUMOUR-BEARING RATS.
R. A. ROBINS, Cancer Research Campaign
Laboratories, University of Nottingham.
During in vitro experiments attempting to
induce cellular cytotoxicity by syngeneic
lymphocytes to chemically induced rat
tumours, and to boost the cytotoxicity of
lymph node cells from rats exposed to tumour
in vivo, it was observed that lymph node
cells from rats bearing a transplanted methyl-
cholanthrene-induced sarcoma became highly
cytotoxic when cultured without addition
of tumour antigen. This cytotoxicity could
be very strong: significant reduction in
target-cell survival wvas observed with 100
effector cells per wvell in a 125IUdR post-
label microcytotoxicity test (effector:target
ratio of 1:5); at E:T ratios of 10:1, over
90% cytotoxicity was obtained. In contrast,
cultured lymph node cells from normal rats
only showed low levels of cytotoxicity at
relatively high E:T ratios. Cultured lymph
node cells from tumour-bearing and normal
rats were also tested in a 5ICr-release assay.
Cytotoxicity w%as not detected in this assay,
even with a 17-h incubation period and high
E:T ratios using lymphocyte preparations
shown to be highly cytotoxic in a 24-48-h
post-label microcytotoxicity test. At least 4
days of culture were necessary for augmented
cytotoxicity to be detected, but cytotoxicity
did not increase further between 4 and 7 days
of culture. Yields of lymphocytes were norm-
ally between 40 and 5000 after 7 days.
Cultured lymphocytes could be stored in
liquid N2 after programmed freezing, and
almost full cytotoxic activity recovered after
thawing. These experiments show that potent
cytotoxic activity can be generated in lym-
phocyte culture, and that some target-cell
systems may require a microcytotoxicity test
to detect cytotoxicity. The exact culture
requirements for the development of cytoxi-
city and the nature and mechanisms of its
effector phase are at present under investi-
gation.
THE USE OF A 5lCr-RELEASE TEST
FOR THE DETECTION OF COMPLE-
MENT-DEPENDENT CYTOTOXICITY
OF RAT HEPATOMA-BEARER
SERUM. M. R. PRICE, Cancer Research
Campaign Laboratories, University of Not-
tingham.
A short-term 5ICr-release test was devel-
oped for the detection of complement-
dependent cytolytic activity of sera from
donors bearing an aminoazo-dye-induced rat
hepatoma for transplanted tumour cells.
Cytotoxicity was evident in the serum of
donors bearing i.p. implants of hepatoma,
but not in sera from animals bearing s.c.
transplants or immunized with y-irradiated
tumour tissue. Sera from syngeneic multi-
parous donors sensitized to tumour-associated
embryonic antigens, also failed to exhibit a
cytotoxic response against tumour cells.
Cytotoxic tumour-bearer sera displayed indi-
vidually distinct, tumour-specific reactivity
against hepatoma target cells which, with
selected sera, was still detectable at final
dilutions of 1/100. Although these sera con-
tained tumour-specific IgG antibody demon-
strable using the indirect membrane-immuno-
fluorescence test, cytolytic activity fraction-
ated in the 19s region of Sephadex G200 gel-
filtration column eluates. This reactivity was
removed by absorption w-ith cells of the same
hepatoma as that borne by serum donors,
whereas absorption with cells of other
hepatomas was without effect. The test
developed is both objective and reproducible
and, used in conjunction with the charac-
terized syngeneic serological reagents avail-
able, it should prove of value for the quanti-
tation of tumour antigens associated with
chemically induced rat hepatomas.
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ANTIGENIC HETEROGENEITY
WITHIN PRIMARY 3-METHYL-
CHOLANTHRENE-INDUCED RAT
SARCOMAS. M. V. PIMM, Cancer Research
Campaign Laboratories, University of Not-
tingham.
Studies by Prehn (1970) J. natn. Cancer
Inst. 45, 1039, with primary 3-methylcho-
lanthrene (Mc)-induced mouse sarcomas have
demonstrated the possibility of antigenic
heterogeneity within individual established
tumours, so that a transplant line initiated
with tissue from one part of a primary sar-
coma was occasionally antigenically distinct
from a line established from another part of
the same tumour. In the present study the
immunogenicities of in vivo lines established
from primary Me-induced rat sarcomas have
been compared with those of lines initiated
from tumour recurrences at the site of the
primaries' surgical excisions. Lines from 2/4
primary sarcomas showed little or no immu-
nogenicity, as assessed by protection to
challenge afforded by graft excision or
implantation ofirradiated tissue. In contrast,
lines from all 4 recurrences were immuno-
genic, giving protection against up to
5 x 106 tumour cells. Most importantly, with
all 4 tumours, lines established from recur-
rences were antigenically distinct from lines
from their original primary sarcomas, so that
immunization with regrowth lines gave no
protection to the lines from the primaries,
and vice versa. These studies support the
concept that primary Mc-induced tumours
may be antigenically heterogeneous, and
demonstrate that outgrowth of a second,
antigenically distinct, tumour follows surgical
removal of the primary. These findings also
have implications for the design of immuno-
therapy protocols for recurrences or meta-
stases from experimental or even human
tumours.
ULTRASTRUCTURAL STUDIES OF
INTERACTIONS BETWEEN HOST
INFLAMMATORY CELLS AND
TUMOUR CELLS WITHIN TRANS-
PLANTABLE HAMSTER FIBROSAR-
COMAS. R. G. P. PUGH-HUMPHREYS,
Experimental Pathology Unit, Department of
Zoology, Aberdeen University.
Transplantable malignant fibrosarcomas,
produced initially by s.c. injection of syn-
geneic hamsters with polyoma-virus-trans-
formed BHK 21/C13 fibroblasts, grew rapidly
and invaded adjacent host muscle and con-
nective tissue. Host inflammatory cells mere
observed, dispersed singly and in groups
within tumour tissue, and these cells appeared
to mediate focal necrosis of tumour cells
-which could not be accounted for simply
by lack of tumour vascularization or coagula-
tion necrosis. Ultrastructural studies revealed
the presence of plasma cells and aggregates
of lymphocytes and phagocytes among the
tumour cells, which are indicative of a host
immune response against the tumour (Moore,
Nisbet and Haigh (1973) Br. J. Cancer, 28,
Suppl. 1). Ultrastructural examination of
contacts between lymphocytes and tumour
cells did not reveal the presence of any
specialized intercellular junctions although
protrusion of lymphocyte pseudopodia into
tumour cells and tumour-cell lysis were
observed. Endocytosis and destruction of
tumour cells by polymorphonuclear leuco-
cytes (PMNs) and mononuclear phagocytes
were observed; whereas PMNs engaged in
microphagocytosis (i.e. phagocytosis ofsmall
portions of tumour cells) the mononuclear
phagocytes attempted to engulf entire cells.
The mononuclear phagocytes had the ultra-
structural appearance of "activated macro-
phages" (Carr (1973) The Macrophage: a
review of ultrastructure and function, Acad.
Press) and appeared to mediate much of the
tumour fibroblast destruction as observed
in other tumour systems (Evans (1973) Br.
J. Cancer, 28, Suppl. 1, 19). Accumulation
of intercellular material around many of the
tumour fibroblasts appeared to afford these
cells protection from direct contact and
attack by host inflammatory cells.
ALVEOLAR MACROPHAGE CYTO-
TOXICITY IN THE DOG. N. T. GORMAN,
Oncology Unit, School of Veterinary Clinical
Studies, Cambridge University.
The cytotoxicity of alveolar inacrophages
from a total of 33 dogs has been examined
using the 51Cr-release assay with allogeneic
long-term tissue-culture cells as targets. It
has been found that alveolar macrophages
from unstimulated dogs (8) do not exhibit
any cytotoxicity. However, in the case of
those animals which received i.v. BCG (10)
and developed diffuse granulomatous lesions
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ofthe lung, the cytotoxicity was marked; this
was not found in 3 dogs which had received
intrathoracic BCG. The observed cytotoxicity
appeared to be non-specific, with a lack of
selectivity between cells of neoplastic origin
or normal canine kidney at the ratios exam-
ined (10:1, 20:1, 40:1). An attempt has
been made to specifically immunize 9 dogs
against allogeneic tumour cells in one of the
following ways:
(a)
(b)
(c)
3 i.v. injections of 5 x 108 cells
3 i.v.injections of 5 x 108 cells plus
3 mg BCG (Glaxo Laboratories)
3 i.v. injections of 5 x 108 cells
sonicated with Freund's adjuvant plus
0 5 mg heat-killed BCG.
In these experiments it was found that only
dogs which received i.v. BCG demonstrated
any cytotoxicity. This however, lacked
specificity for the immunizing cell. In a
further series of 3 dogs which received more
immunizations with Freund's adjuvant, cells
and heat-killed BCG, non-specific cyto-
toxicity has been observed. Examination of
the supernatants of cultures of alveolar
macrophage from both normal dogs and those
which had received i.v. BCG failed to reveal
any soluble factor which could produce the
observed cytotoxicity.
EFFECTS OF CORTISONE ACETATE
AND SPARINE ON THE PRIMARY
LEWIS LUNG CARCINOMA AND ITS
PULMONARY METASTASES AND ON
THE ACTION OF C. PARVUM. T. E.
SADLER, P. D. E. JONES, H. D. MITCHESON
and J. E. CASTRO, Urology and Transplan-
tation Unit, Royal Postgraduate Medical
School, Harnmersmith Hospital, London.
Corynebacterium parvum inhibits the
growth of a variety of animal tumours and
it is now undergoing clinical trials. In man,
this vaccine causes undesirable side-effects,
including nausea and pyrexia. Hydrocor-
tisone and sparine have been used to relieve
these symptoms. In this study, the effects of
cortisone acetate (CA) or sparine on the
growth of the primary Lewis lung carcinoma
and its pulmonary metastases and the action
of C. parvum were investigated in C57BL
mice.
A high dose of CA similar to that used by
Fisher et al. (1976) J. natn. Cancer Inst., 56,
571, had little effect on primary tumour
growth but significantly enhanced metastases.
Iv. C. parvum given to these mice before or
after CA treatment caused no further
tumour inhibition, but significantly reduced
metastases. However, the number of meta-
stases in mice which were given combined
C. parvum and CA was not significantly
different from that found in control mice,
and significantly greater than that found in
mice which received only C. parvum. Thus
CA effectively counteracted the beneficial
antimetastatic action of C. parvum. A low
dose of CA (human equivalent) or sparine
did not alter primary tumour growth or the
antimetastatic action of C. parvum.
We conclude that all drugs being given to
patients to counteract the side effects of
immunotherapy should be examined experi-
mentally to determine their effect on both
primary and secondary tumours.
THE MECHANISM OF THE ANTI-
TUMOUR EFFECT OF GLUCANS AND
FRUCTOSANS. A COMPARISON
WITH C. PARVUM. R. BOMFORD & C.
MORENO, Department of Experimental JImmu-
nobiology, Wellcome Research Laboratories,
Beckenham, Kent.
The antitumour activity induced by glu-
cans (lentinan, yeast cell walls, pseudonigeran,
dextran, DEAE-dextran and dextran sul-
phate) and fructosans (levan and carboxy-
methyl-levan) was compared with the activitv
of C. parvum. The following effects on tumour
systems in CBA mice were assayed: (a) adju-
vant activity on the immune response against
tumour-specific transplantation antigens
(TSTA) with a methylcholanthrene-induced
fibrosarcoma; (b) cytostatic activity of peri-
tonealmacrophages against radiation-induced
leukaemia cells; and (c) inhibition of nodule
formation in the lungs following i.v. injection
offibrosarcoma cells.
All the polysaccharides induced cytostatic
macrophages, but the dextrans and levans did
so only after i.p. and not i.v. injection. Only
lentinan, yeast cell walls and pseudonigeran
were active in the lung-nodule-inhibition
test; and only lentinan and dextran sulphate
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showed slight adjuvant activity for TSTA.
It is concluded that the antitumour activity
induced by these polysaccharides is pre-
dominantly non-specific macrophage-media-
ted and much wNreaker than that found wxAith
C. parvum.
SYNERGISTIC COMBINATION OF
CHEMO- AND IMMUNO-THERAPY
IN A MOUSE TUMOUR SYSTEM. M. T.
SCOTT, Department of Experimental Immuno-
biology, Wellcome Research Laboratories,
Beckenham, Kent.
Treatment of a chemically induced mouse
solid fibrosarcoma, using either non-specific
(C. parvum 350 jug i.v.) or specific active
(s.c. C. parvum mixed with 5 x 105 irradi-
ated tumour cells) immunotherapy, 4 days
after a single dose of cyclophosphamide
(200 mg/kg) was synergistically more effec-
tive than either C. parvum or drug treatment
alone. A contributory factor may be that
cyclophosphamide pretreatment has been
shown to potentiate the specific antitumour
immunity that arises from C. parvuminter-
action with tumour antigen. Systemic C.
parvum before cyclophosphamide will poten-
tiate the antitumour effects of the drug;
previously ineffective low doses becoming
effective. No similar potentiation of the
effects of another alkylating agent, Melpha-
lan, was evident.
ENHANCEMENT OF THE ANTI-
TUMOUR EFFECTIVENESS OF
METHOTREXATE THROUGH SELEC-
TIVE PROTECTION OF NORMAL
TISSUES. G. A. TAYLOR, G. P. BROWMAN
and K. R. HARRAP, Department ofBiochemical
Pharmacology, Institute of Cancer Research,
Sutton, Surrey.
The use of folinic acid (citrovorum factor)
to limit the toxicity of methotrexate (MTX)
to normal proliferating tissues, is an
established clinical procedure during intensive
MTX therapy ((1975) Cancer Chemother. Rep.,
6). In previous reports we have shown that
MTX induces a purineless state in bone mar-
row and small intestine when administered
to mice (Talbot et al. (1976) Br. J. Cancer,
34, 321; Straw et al. (1977) J. natn. Cancer
Inst., 58, 91), the deficiency being established
earlier in the gut than in bone marrow. We
have currently been investigating the possi-
bility that normal proliferating tissues of the
mouse can be protected fromMTX toxicityby
the administration of purine and pyrimidine
nucleosides or bases. It was demonstrated
that a pyrimidine alone could not protect
from the toxic effects of MTX. Howrever,
combinations ofthymidine (TdR) and hypox-
anthine (Hx) (together with allopurinol (Ap))
do protect the mouse from MTX toxicity,
with an efficacy comparable to folinic acid.
Furthermore, rescue of L1210-tumour-bear-
ing animals with TdR/Hx/Ap combinations,
following MTX treatment, can produce a
median survival in excess of that achieved
with folinic-acid rescue. It would seem that
purine/pyrimidine rescue techniques may
exploit selective differences in salvage-
pathw,ay utilization between tumour and
normal tissues, and may have clinical applica-
tion.
DIHYDROFOLATE-REDUCTASE AC-
TIVITY IN MOUSE GUT AFTER
TREATMENT WITH METHOTREX-
ATE, AND RESCUE WITH VARIOUS
AGENTS. A. H. CALVERT and K. R.
HARRAP, Department of Biochemical Pharma-
cology, Institute of Cancer Research, Suttonz,
Surrey.
Recently, considerable attention has been
paid to the selective protection of normal
tissues from the effects of methotrexate
(MTX) by the use ofpurines and pyrimidines,
w%ith the object of increasing the.therapeutic
index ofthis drug (Straw et al. (1977) J. natn.
Cancer Inst., 58, 91). The toxicity of MTX
is dependent on the time for which a 950/
inhibition ofdihydrofolate reductase (DHFR)
is maintained (Goldie et al. (1972) Eur.
J. Cancer, 8, 409; Jackson- and Harrap
(1973) Arch. Biochem. Biophys., 158, 2).
Therefore it is important to assess this para-
meter in addition to a study of the total
plasma and tissue levels of MTX in those
animal models used for testing rescue proto-
cols. A technique has been developed for
measuring the in vivo inhibition of DHFR,
making allowance for the extracellular fluid
contribution of MTX to the total, and the
kinetic constants of the enzyme concerned.
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This has been applied to the small intestine
from C57BI mice treated with 400 mg/kg of
MTX followed by rescue with either saline,
thymidine, hypoxanthine + allopurinol,
hypoxanthine + allopurinol + thymidine or
folinic acid. In all the rescued groups,
methotrexate levels in plasma, bone marrow
and gut were higher than those in the saline
control group. In all groups, inhibition of
DHFR was greater than 9500 for the duration
of the rescue period (5 days). These results
suggest that the survival of the rescued
animals must depend upon an endogenous
supply of reduced folates, or purines and
pyrimidines, rather than recovery of DHFR
activity in the gut.
EFFECTOR REGULATION: A POTEN-
TIAL NEW CHEMOTHERAPEUTIC
STRATEGY. R. M. PAINE and K. R.
HARRAP, Department of Biochemical Pharma-
cology, Institute of Cancer Research, Sutton,
Surrey.
At the last AGM we described how it was
possible to enhance the toxicity of adenosine
(AR) to lymphoid cells with coformycin
(Cf), a tight binding inhibitor of adenosine
deaminase (EC 3.5.4.4) (Harrap et al. (1976)
Br. J. Cancer, 34, 309). In the case of mito-
genically-stimulated lymphocytes it was
apparent that the biochemical mechanism
underlying cytotoxicity was a build up of
deoxyadenosine triphosphate (dATP) and
an associated inhibition of DNA synthesis
(see also Harrap and Paine (1977) Adv. Enz.
Regln, 15). In the present investigation, we
have found that deoxyadenosine (AdR) is
toxic to cultured L1210 cells in presence of
deoxycoformycin (dCf). Giant-cell formation
is detected by 24 h, due to inhibition of DNA
synthesis in the face of continued RNA and
protein synthesis (imbalanced growth). The
primary metabolic lesion would appear to be
inhibition of ribonucleotide reductase (EC
1.17.4.1) via a build up of the negative
effector, dATP. Furthermore, treatment of
L1210-tumour-bearing animals with binary
combinations of AdR and dCf produces
extension of survival time. We propose that
selective enhancement of the regulatory
properties of effector molecules provides a
realistic means of inhibiting tumour growth.
SOME KINETIC PARAMETERS OF
PURINE SALVAGE ENZYMES. D. C.
TALBOT and K. R. HARRAP, Department of
Biochemical Pharmacology, Institute of Cancer
Research, Sutton, Surrey.
In view of the use of hypoxanthine (Hx)
in selective methotrexate (MTX) rescue
schedules (Strawr et al. (1977) J. natn. Cancer
Inst., 58 91; Talbot et al. (1976) Br. J. Cancer,
34, 321), and the toxic effects of adenosine
(AR) to normal and malignant lymplhoid
cells (Harrap et al. (1976) Br. J. Cancer, 34,
321) it became important to understand the
differences in purine salvage activity in a
number of cell types. We have compared
kinetic parameters of hypoxanthine guanine
phosphoribosyl transferase (HGPRT) (EC
2.4.2.8) from L5178Y cells growing in
purine-free (Pu-) and purine-supplemented
(Pu+) medium. A 5-fold increase in Vmax of
HGPRT from L5178Y (Pu+) was observed
8 weeks after transferring cells into culture.
In the L5178Y (Pu-) line a 4-fold decrease in
Vmax was found. The L5178Y (Pu-) line had
a greater rate of purine synthesis de novo
than L5178Y (Pu+). Little change in the Kml
for Hx was observed in HGPRT from either
line. Selective potentiation ofthe toxic effects
of AR by inhibitors of adenosine deaminase
(ADA) (EC 3.5.4.4) depends on the relative
rates of phosphorylation and deamination of
AR. Adenosinekinase (AK) (EC 2.7.1.20) from
mouse liver, spleen, marrow and L1210 cells
had a greater affinity for AR than ADA, but
the Vmax of ADA was -100-fold greater
than AK in these tissues. In L1210, the
deamination/phosphorylation ratio increased
markedly with AR concentration. This was
notobserved inspleen, liveror marrow.Studies
have also indicated that AK from L1210 is
substrate-inhibited at high concentration of
AR. These studies show the importance of
the kinetic parameters of purine salvage
enzymes in relation to Hx rescue and AR
toxicity.
AN ASSESSMENT OF ORAL METHO-
TREXATE SYRUP. J. G. MCVIE, J.
PAXTON, B. W. WHITING, M. SOUKoP and
K. C. CALMAN, Department of Clinical
Oncology, We.stern Infirmary, Glasgow.
A new formulation of methotrexate (MTX)
was sought, to cope with the high doses in
current practice. The standard tablet size
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is 2-5 mg, and so a syrup was prepared which
had a final concentration of 2 mg MTX per
ml. It was tested in the clinic and was
accepted well by our patients. Samples ofthe
syrup were assayed 8 times throughout 32
days of storage at room temperature or
4°C by a radioimmunoassay for MTX. There
was no alteration at all in the concentration
of MTX throughout the experiment. Six
patients had serial blood and urine samples
taken after ingestion of the oral syrup at a
dose of 50 mg/M2 and then a week later after
injection ofan identical dose i.v. The relative
availability of the drug varied from 15 to
62%. This indicated that absorption of the
oral drug had taken place in all the patients,
but the bio-available levels were consider-
ably less in all cases than when the drug was
given i.v. in the same dose. The mean
yt1/2 in hours was 4-14 h for the i.v. route and
3412 h by the oral route. There was marked
individual variation in the handling of MTX
in the 6 patients irrespective of the route of
administration. We conclude that oral MTX
may be given in a higher dose and possibly
more frequently than i.v. MTX. Further,
MTX syrup is stable over 32 days, and has
proved extremely palatable to large numbers
of patients.
TREOSULFAN (DIHYDROXYBUSUL-
PHAN) IN THE MANAGEMENT OF
OVARIAN CARCINOMA. J. J. FENNELLY,
St Vincent's Hospital, Dublin.
Treosulfan (dihydroxybusulphan) is an
alkylating agent which was synthesized by
Feit in 1964. It has been found effective in
Dunning Leukaemia and Lymphoma 8.
Because of reports of Lundvall, Sorenson
and Larsen (1973, Acta obstet. Gynaec.
Scand. Suppl. 22) of benefit in ovarian
carcinoma the author has evaluated Treosul-
fan in 40 patients with ovarian carcinoma.
Treosulfan was given as 250-mg capsules
q.i.d. daily for 4 weeks on alternate months.
Depression of white cell count and platelet
count occurred in similar pattern to that of
other alkylating agents, but recovery was
rapid. In addition a significant depression of
haemoglobin occurred.
Of 40 patients treated, 12 (30%) showed a
complete response for a mean duration of
15/12. Eleven (27%) showed a partial
response for a mean of7 months. 57% showed
a total response.
Treosulfan is well tolerated, has a low level
of gastrointestinal toxicity, is a predictable
and transient marrow depressant, and gives
response rates similar to other alkylating
agents.
COLCHICINE ULTRASENSITIVITY
OIF PERIPHERAL BLOOD LYMPHO-
CYTES IN LYMPHOID MALIGNAN-
CIES. J. H. SCARFFE, J. PRUDHOE and D.
CROWTHER, CRC Department of Mledical
Oncology, Christie Hospital and Holt Radium
Institute, Manchester.
The ultrasensitivity of chronic lymphatic
leukaemia cells cultured for 20 h with
colchicine, compared with normal lympho-
cytes, has been described by Thompson et al.
(1972, Scand. J. Haemat., 9, 231). We have
used this technique to study peripheral
blood lymphocytes in other lymphoid malig-
nancies. Peripheral blood lymphocytes were
incubated at 370C in 5% C02 for 20 h at
concentrations of 0, 10-2, 10-3, 10-4, 10-5,
10-6, 10-7 M colchicine in TC199. The cells
were wet fixed on slides, stained and the
percentage of cells with pyknotic nuclei
counted. Twenty normal controls all showed
less than 20% pyknosis at all concentrations
less than 10-2 M colchicine. Twenty-six ill
controls, with diseases other than lymphoid
malignancies, showed a slightly higher range
of pyknosis up to 20% at concentrations less
than 10-2 M. We were able to confirm the
ultrasensitivity of chronic lymphatic leukae-
mia cells in 17/18 cases studied. Forty and
99% pyknosis at the lower concentrations of
10-7 and 10-6 were observed, compared with
the concentration of 10-2 M required for
pyknosis in normal lymphocytes. The one
resistant case was initially sensitive but later
developed resistance, although the absolute
number of sensitive cells remained approxi-
mately the same. Peripheral blood lympho-
cytes in 17 cases of multiple myeloma were
not found to be ultrasensitive. However 20/51
patients studiedwithnon-Hodgkin lymphoma
showed an abnormally high percentage of
pyknotic cells. It was expected that ultra-
sensitivity would be found more commonly
inthewelldifferentiated pathologygroups,but
results were similar for both well and poorly
differentiated groups. None of the patients
studied was frankly leukaemic, all the abnor-
mal group had lymphocyte counts less than
7000/,ul.
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GROWTH KINETICS OF HUMAN
TUMOUR XENOGRAFTS UPON
SERIAL PASSAGE IN IMMUNE-
DEPRIVED MICE. J. A. HOUGHToN and
D. M. Taylor, Radiopharmacology Department,
Institute of Cancer Research, Sutton, Surrey.
Using the tumour systems previously
described (Houghton and Taylor (1976) Br.
J. Cancer, 34, 313), preliminary studies have
shown increased growth rates -within the
first 10 serial passages in 5/6 lhuman colorec-
tal tumours maintained in immune-deprived
CBA/LAC mice. Using bilateral implants,
the percentage of single tumour takes
(lecreases significantly with serial passaging,
with hosts producing either two or no
tuniours. These values deviate frorn tlhose
expected from a binomnial distribution after
the first one to two passages, more single
takes beingr predicted than occur. Grow%th
rates of individual tumours, calculated both
at 0 4 cm3 volume and during exponential
growth, can differ widely on very early
passages, and subsequently becomie more
uniform after the first 2-4 passages. V'olume-
doubling times of tumours growing within
the same animal are similar, and growth-rate
variation within a passage is such that the
variance of growAth rates of tumours estab-
lished in different mice is greater than those
of tumours grow-ing in the sarne animal.
Hence fast and slow-growing turmours occur
in separate hosts. Tumours wThich occur as
single takes also have very varied grow-th
rates witlhin a passage. Results thus indicate
a trend toward increased and more uniform
growth rates. However, actual growth rates
and takes per mouse Avithin a passage may
l)e dictated by the host. This could depend
on the extent of individual host immune-
deprivation which may influence the rate of
cell loss wNNithin a tumour.
CHANGES IN 3H-THYMIDINE
UTILIZATION AS A PREDICTOR OF
GROWTH DELAY IN FOUR HUMAN
COLONIC TUMOUR XENOGRAFTS.
P. J. HoUGHTON, Institute ofCancer Research,
Sutton, Surrey. (Introduced by D. Ml. Taylor.)
Changes in the fractional incorporation
(FI) of radiolabelled precursors into DNA
have been examined in 4 xenograft lines
maintained in immune-deprived mice, and
have beenrelated togrowth inhibition induced
by the same treatment. The FI measures the
proportion ofthe total radiolabelled precursor
in the tissue sample which is incorporated
into DNA within 1 h of administration.
The FI is not affected by variation in pre-
cursor concentration achieved over a 10-fold
range, which may occur in irregularly per-
fused tumours. Significant growNth inhibition
has been observed only when the cytotoxic
agent produced a considerable and prolonged
depression in 3H-thymidine Fl. Tumour
growth rate returns to its pretreatment value
at a time wAhen Fl returns to the pretreatment
level (FI recovery time). Following adminis-
tration of cyclophosphamide, 5-fluouracil, or
actinomycin D, the growtlh delay and FT
recovery time are always similar. The initial
depression of 3H-thymidine FT into DNA
is a poor indicator ofthe actual growth delay,
as different xenograft lines exhibiting the
same depression 1 to 2 days after treatment
may show considerably different FT recovery
times, w-hich are similar to the measured
growth delay. How-ever, wNithin a tumour
line there is a relationship between the initial
depression of 3H-thymidine FI and both Fl
recovery time and growth delay, which
appears to be independent of the mechanism
by which the agent induces cell kill.
CYCLOPHOSPHAMIDE AND CIS-
DICHLORODIAMMINE PLATINUM
(II): A PERSPECTIVE IN SCHEDUL-
ING. K. D. TEW and D. M. TAYLOR, Radio-
pharmacology Departnt/ent, Institute of Cancer
Research, Suttonl.
Fractional incorporation (FI) of 3H-thymi-
dine (proportion of total tissue 3H incor-
porated into DNA) has been used success-
fully as a parameter for judging temporal
scheduling of cyclophosphamide (CY) and
cis-dichlorodiammine platinum (DDP). A
difference in recovery time of FT following a
dose of 100 mg/kg CY between tumour
(>12 days), gut (2-3 days) and bone marrow
(4 days) suggested a basis for a normal tissue-
sparing drug regimen wNhen administering
double-dose CY-DDP therapy. There were
0/10 sur-vivors when 100 mg/kg CY and
8 nmg/kg DDP wrere administered together
1/10 survivors when the doses were separated
by 1 day and 10/10 survivors when separated
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by 4 days. This 4-day interval w-as con-
sidered to allow gut and bone marrow
recovery, factors crucial to the survival of
the animal, before the second insult. These
three combinations were similar in their anti-
tumour effect in being slightly more than
additive. CY was more myelotoxic than
DDP; DDP was more gut-toxic. The recovery
of bone-marrow cellularity was 2 days later
than Fl recovery. Peripheral white blood
counts were reduced for a still longer period
of time. The possibility of multiple drug
administration based upon these findings
remains to be elucidated.
PHARMACOKINETICS OF PLATI-
NUM ANTITUMOUR AGENTS IN
MOUSE ORGANS. B. W. MALERBI and
G. ABEL, Johnson -Matthey Research Centre,
Sonning Common, Oxon and Chester Beatty
Research Institute, London. (Introduced by
T. A. Connors.)
In antitumour screening tests in BALB/C
mice, cis-diamminedichloroplatinum (II)
(DDP), cis-dichlorobis(cyclohexylamine)
platinum (II) (CHP), and cis-dichlorobis
(4-methylcyclohexylamine)platinum (II)
(MCHP) gave LD50 values of 16, 3200, and
1180 mg/kg. Corresponding ID90 doses were
2-4, 12 and 990 mg/kg respectively. To
elucidate these differences, these compounds
w,ere injected i.p. into healthy BALB/C mice.
Animals were sacrificed at intervals spanning
15 min to 14 days after injection, and plati-
num analyses were performed on the liver,
spleen, kidneys, heart, lungs, small intestine,
large intestine, brain, skeletal muscle, bone
and skin. Although all these compounds were
stored in the liver, the effect was more marked
for CHP and MCHP. In the kidneys, DDP
produced an initial peak that declined
rapidly, whereas CHP and MCHP produced
lower steady levels. The large intestine
showed a late rise in CHP and MCHP which
was not observed wvith DDP. None of the
compounds showed superior ability to cross
the blood-brain barrier. The pharmacokinetic
behaviour of CHP and MCHP in the kidney
may explain their low toxicity compared
with DDP. DDP is known to be excreted
mainly via the kidneys, but the high levels
of CHP and MCHP found in the intestines
suggest that biliary excretion predominates
for them. The differences in uptake are
explicable by low aqueous solubility of CHP
and MCHP, which persist in the peritoneum
for several days. This slowr uptake and sus-
tained concentration in the tissues shown by
CHP may explain its good antitumour
activity. However, MCHP has similar
pharmacokinetic behaviour but very low
activity.
THE MECHANISM OF INTER-
ACTION OF TWO PLATINUM CO-
ORDINATION COMPLEXES WITH
RADIATION IN CHO CELLS IN VITRO.
A. H. W. NIAs and IRENA I. SZUMIEL,*
Glasgow Institute of Radiotherapeutics and
Oncology, Belvidere Hospital, Glasgow.
The effects of two platinum coordination
complexes have been compared on CHO cells
in vitro. While cis-dichlorobisisopropylamine
trans-dihydroxy platinum IV (CHIP) is
very soluble in water, cis-dichlorobiscyclo-
pentylamine platinum II (PAD) is insoluble
and was dissolved in DMSO. Dose-response
curves after a 15 min exposure to CHIP
anid PAD were similar in shape, wvith final
exponential slopes of 16 and 14 jug/ml
respectively. The shoulder of the CHIP
curve was much larger (N-300) than that
for PAD (N=7).
Drug-radiation combination experiments
showed a synergistic effect only when radia-
tion follow%ed a drug dose level high enough
to reduce cell survival from the shoulder
towards the exponential part of these dose-
response curves. After PAD, the highest
enhancement ratio was 1 59, whilst a ratio of
1P73 was found after a comparatively lower
dose of CHIP. No cycle-phase specificity
was found following PAD alone, but com-
binations with radiation showed more syner-
gism in the G1 and late-S position of the cell
cycle than in mid-S.
These survival data, together with the
results of other studies with PAD, including
an absence of split-dose sparing and a pattern
of chromatid aberrations, are compatible
with the "molecular theory of cell survival"
(Chadwick, Leenhouts, Szumiel and Nias
(1976) Int. J. Radiat. Biol., 30, 511) which
* IAEA Fellow, Department of Radiobiology
and Health Protection, Institute of Nuclear
Research, 03-195, Warsaw, Poland.
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provides an explanation of the cytotoxic
action of the platinum complex and its
synergistic interaction with radiation.
THE EFFECT OF ICRF 159 ON
ACCUMULATION AND REPAIR OF
RADIATION DAMAGE. I. W. TAYLOR
and N. M. BLEEHEN, MRC Unit of Clinical
Oncology and Radiotherapeutics, Cambridge
University Medical School.
ICRF 159 has been shown to increase the
sensitivity to X-irradiation of exponentially
growing EMT6 mouse tumour cells in vitro
(Taylor and Bleehen (1977) Br. J. Canc(r, 36).
This is found only with ICRF 159 exposure
times greater than 14 h, and only w%hen the
drug is given prior to irradiation. A 24-h expo-
sure to 200 ,ug ICRF 159 before irradiation
leads to a reduction in the radiation survival-
curve shoulder (Dq=129 rad) compared with
non-drug-treated controls (Dq=509 rad). This
would suggest a loss of ability to accumulate
or repair sub-lethal damage. The split-dose
radiation response was examined using cells
which had either a 6-h or a 24-h exposure
to 200 jig ICRF 159 before the two doses of
radiation and compared to control cells
irradiated under similar conditions. In the
ICRF 159-treated cells the drug was present
during the interval between radiation doses.
In all three cases, the cells, whether drug-
treated or not, were found to have recovered
75-85% of their previously measured Dq.
The reduction in Dq found for cells treated
with ICRF 159 for 24 h, therefore, cannot be
explained by the drug preventing or inhibiting
repair of sub-lethal damage. It would appear
therefore, that prolonged pretreatment with
ICRF 159 reduces the cells ability to accumu-
late sub-lethal damage.
STUDIES OF RESISTANCE TO
ICRF 159 IN CELL LINE BS/159-1. K.
WHITE and A. M. CREIGHTON, Imperial
Cancer Research Fund, London.
The isolation of a cell line (BS/159-1),
derived from BHK 21S cells and showing
resistance to the antitumour drug ICRF 159,
has been previously reported (White and
Creighton (1976) Br. J. Cancer, 34, 323).
Protein synthesis inhibitors (e.g. puromycin
and cycloheximide) normally allow cells to
progress into mitosis for 1 h only, after
which time cells will no longer cross the G2/M
border. BS/159-1 cells, however, are not
inhibited in this way, mitotic cells continue
to accumulate. This suggests that either the
protein requirement for mitosis is already
met, or the protein-synthesis mechanisms in
BS/159-1 cells are resistant to these inhibitors.
The latter seems unlikely, since BHK 21S
and BS/159-1 cells are equally sensitive to
puromycin inhibition of protein synthesis.
ICRF 159 has no direct effect on protein-
synthesis mechanisms per se.
It is possible that ICRF 159 inhibits the
function (either directly or indirectly) of a
protein required for mitosis. The availability
and/or nature ofthis protein may be modified
in BS/159-1 cells.
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PART II: POSTER EXHIBITS
ABSENCE OF NUCLEOSIDE EFFECT
IN CELLS IRRADIATED BY FAST
NEUTRONS. A. FERLE-VIDOVIC, D.
PETROV16, J. SORIC, D. RENDIC and I.
SLAUS, Institute Ruder Boskoric, Zagreb,
Yugoslavia.
Breakdown products of DNA can increase
the survival of irradiated cells. This had been
studied extensively by employing deoxyri-
bonucleosides in L cells (Petrovi6, Ferle-
Vidovic, Habazin, Vukovic (1970) Int. J.
Radiat. Biol., 18, 243) after X irradiation.
In the present work, L 929 cells were irradi-
ated by neutrons of different energies:
4-5 MeV mean energy and 14-5 MeV mono-
energetic neutrons. For comparison, cells
were also irradiated by 60Co gamma rays.
Following irradiation cells were treated by
an equimolar solution of deoxyribonucleo-
sides (50 ,ug/ml), and effect on their survival
measured. Results showr that nucleoside
treatment was efficient after the low LET
irradiation: gamma rays survival curves
were altered by nucleosides in terms of
significantly increased extrapolation numbers
only, but without Do change. Cells irradiated
by neutrons from either ofthe two sources did
not respond to nucleoside treatment, and
consequently their survival curves remained
unaltered. These results show that the
nucleoside effect does occur after lowr LET
irradiation, but apparently not following
high LET irradiation. Since nucleosides as
well as other cell breakdown products are
released in irradiated tumours due to mass
cell destruction, such nucleoside effect could
possibly enhance the cell survival and thus
affect the result of radiotherapy. Absence of
the nucleoside effect in case of high LET
irradiation may therefore be an additional
potential gain from neutrons in radiotherapy.
CELL CYCLE ANALYSIS IN VITRO
USING FLOW CYTOFLUORIMETRIC
TECHNIQUES. J. V. WATSON, MRC
Clinical Oncology and Radiotherapeutics Unit,
Cambridge University Medical School.
Flow cytofluorimetric technology enables
the DNA content of cells in a single cell
suspension to be estimated (Trujillo and van
Dilla (1972) Acta Cytol., 16, 26). The first
peak ofa characteristic histogram corresponds
to the fluorescence emitted by the DNA-
fluorochrome complex of cells in G1. The
emission of cells in G2 + M is double that of
cells in G1 resulting in a second peak at,
double the abscissa scale reading, channel
number. Two computer models are presented
which can analyse the experimental data.
The first employs age distribution theory
(Steel (1968) Cell & Tissue Kinet., 1, 193) to
give estimates of not only the proportions of
cells in each phase, but also of the relative
phase durations. This model can be used for
populations containing a mixture of cycling
and non-cycling cells, but it is concluded
that reliable estimates of the grow%th fraction
can only be obtained if the relative phase
durations are known. Good agreement
between the computed proportion in S phase
and the 3H-TdR labelling index was found
in the five cell lines analysed. A second model
based upon the theory presented by Hart-
mann and Pederson ((1970) Cell & Tissue
Kinet., 3, 1), has been produced to analyse
the desynchronization of EMT6/M/CC cells
following mitotic selection synchronization.
Good agreement was obtained between the
cytofluorimetric data and results from parallel
3H-TdR studies.
STUDIES ON A DNA CONTAINING
MATERIAL FROM P388 CELL
LYSATES HIGHLY SENSITIVE TO
IONIZING RADIATION. D. G. POPPITT
andB. W. Fox, Paterson Laboratories, Christie
Hospital and Holt Radium Institute,
Manchester.
The sedimentation behaviour of a DNA
complex material resulting from lysis of
P388 lymphoma cells follow%iing X- and
gamma-irradiation has been studied on
isokinetic sucrose gradients with an initial
sucrose concentration of 2000. A decreased
sedimentation rate followNing irradiation
throughout the range from 5 rads to 10 krads
has been observed. Post-irradiation incuba-
tion has suggested that a partial reconstitu-
tion of this material may occur within
approximately 6 h.
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DEGRADATION OF ERROR PRO-
TEINS IN HeLa CELLS. D. N. WHEATLEY,
M. R. GIDDINGS, M. S. INGLIS and J. H.
STEVENSON, Department of Pathology, Aber-
deen University Medical School.
The possibility that changes in cell beha-
viour seen in phenomena such as ageing,
malignant transformation, differentiation and
mutation may be the result of error (or
accumulation of errors) in protein biosyn-
thesis (e.g. Orgel (1973) Nature, 243, 441;
Talmud and Lewis (1974) Nature, 249, 563;
Bradley and Schimke (1973) in Intracellular
Protein Turnover, Academic Press, p. 311)
is currently receiving much attention. The
hypothesis raises the question of whether
a special surveillance mechanism exists
through which error proteins are detected
and preferentially removed by cells, and the
problems of what happens if it breaks down
or is overloaded. In HeLa cells allowed to
incorporate amino acid analogues instead
of natural amino acids, we found no evidence
of preferential degradation of anomalous
proteins. In some cases, the consequences of
analogue incorporation resulted in cells
becoming degenerate with a subsequently
elevated breakdown of all cellular proteins.
The results favour the hypothesis that
degradation follows first order kinetics for
both normal and abnormal proteins and is
due to a common intracellular proteolytic
system operating in a stochastic manner.
ACQUIRED DRUG RESISTANCE:
ENHANCEMENT OF THE INTRA-
NUCLEAR REACTIVITY OF ALKYL-
ATING DRUGS. R. WILKINSON and K. R.
HARRAP, Department of Biochemical Pharma-
cology, Institute of Cancer Research, Sutton,
Surrey.
Alkylating agents find wide usefulness in
the treatment of malignant diseases, though
their effectiveness is impaired frequently by
the development of acquired resistance. It
becomes important therefore to devise
schedules which, ideally, are antagonistic in
terms of host toxicity and synergistic in
relation to their antitumour effects. Alkylat-
ing agents are frequently administered in
combination with steroids: we have found
that binary combinations of chlorambucil
and prednisolone can be administered to
tumour-bearing (Yoshida sensitive and resis-
28
tant) Wistar rats, producing a greater thera-
peutic index than can be achieved with
chlorambucil alone. Similar results can be
obtained with prednimustine (Leo 1031) a
prednisolone ester of chlorambucil. Previous
work in this laboratory has shown that
chlorambucil induces morphological and
chemical changes in the structure of nuclear
proteins of drug-sensitive cells, though not of
resistant ceBs (Riches and Harrap (1973)
Cancer Res., 33, 389; Riches and Harrap
(1975) Chem.-Biol. Interactions, 11, 291).
However, it willbe shown that in the presence
of prednisolone, similar changes can be
produced in the chromatin of drug-resistant
cells. We have also found that the time
sequence of steroid administration, in rela-
tion to that of the alkylating agent, modifies
the pattern of DNA cross-linking in the
tumour, possibly by disruption of repair
processes.
MYELOTOXICITY OF METHOTREX-
ATE IN ANIMALS WITH PYOGENIC
INFECTION. B. HARDING and I. C. M.
MACLENNAN, NuJfield Department of Clinical
Medicine, Radcliffe Infirmary, Oxford.
This poster reports an investigation of the
hypothesisthatincreasedproliferativeactivity
by neutrophil precursors induced by pyogenic
infection will result in an increase in the
susceptibility of these cells to damage by
methotrexate (MTX). Rats were stimulated
into prolonged increased neutrophil produc-
tion by the induction of a unilateral pyo-
hydronephrosis. Consistent profound neutro-
penia was seen when MTX was given during
the first 2 days of infection, but thereafter
greater neutropenia than that observed
in non-infected rats was only observed in
occasional animals. There was a significant
correlation between the degree ofneutropenia
induced by MTX and the day after MTX
upon which this occurred. It is argued that
the main target for myelotoxicity by MTX is
the myelocyte and that its precursors are
relatively insensitive.
MECHANISMS OF IN VITRO AND IN
VIVO RAZOXANE RADIOSENSITIZA-
TION. M. BARKER-GRIMSHAW, Chemo-
therapy Department, Imperial Cancer Research
Fund, London. (Introduced by Q. Hellman.)
Razoxane (ICRF 159) produces radio-
sensitization in vitro and in vivo. Various
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mechanisms have been suggested to account
for this effect, viz: the angiomorphic effect;
blockage of cell cycle progression at G2/M;
inhibition of repair of radiation-induced
DNA damage and general synergism with
other antitumour agents, but which, if any
of these mechanisms is involved is not yet
clear. Experiments to test whether tumours
treated with razoxane lhad an increased blood
flow as a result of the angiometamorphic
effect have been essentially negative. On the
other hand, a higher oxygen concentration
was found in such tumours even when treat-
ment w%as delayed until 1 h before measure-
ments were made. Compared with the inhibi-
tory effect of razoxane or radiation alone, the
combination of the two in the treatment of
sarcoma S180 was much more effective even
when razoxane was given 3 h after the
radiation. Of the mechanisms of radiosensi-
tization suggested for razoxane therefore that
of inhibition of repair of radiation-induced
DNA damage seems to be the most, likely.
FACTORS DETERMINING THE
RESPONSE TO 5-FLUOROURACIL
IN HUMAN COLONIC TUMOUR
XENOGRAFTS. P. J. HOUGHTON, J. A.
HOUGHTON and D. M. TAYLOR, Division of
Radiopharnkacology, Institute of Cancer
Research, Sutton, Surrey.
The relationship between the inhibition
of 3H-deoxyuridine incorporation into DNA
and growth delay followxving 5-fluorouracil
administration has been examined in 4
humain colonic tumour xenografts growing in
immune-deprived mice. The dose of 5-
fluorouracil producing 5000 inhibition of
3H-deoxyuridine incorporation in vivo (ID50)
in 2 tumour lines was less than that found for
normal (mouse) "limitinlg" tissues, but greater
in the other tumour lines. After 5-fluorouracil
(100 mg/Kg ID90 in all tumour lines) only
tumours of one line showved a depression in
3H-thymidine incorporation into DNA and
growth delay, whereas tumours of the other
lines showed an increase in uptake and
incorporation of this nucleoside into DNA
during the first, 4 days, and no growAth
delay. Recovery of 3H-deoxyuridine incor-
poration to the pretreatment level varied
from 150 to over 600 h between tumour lines
after 100 mg/Kg 5-fluorouracil. The differ-
ence betwreen the recovery times for de novo
(3H-deoxyuridine) and "salvage" (3H-thymi-
dine) pathways after 5-fluorouracil treatment
has been used as a measure of the ability
of that human tumour ]ine to utilise the
"salvage" pathway for thymidine triphos-
phate synthesis in the presence ofthymidylate
synthetase inhibition. There appears to be no
correlation between the degree or duration
of thymidylate synthetase inhibition and
gro-wth delay, following 5-fluorouracil admini-
strationi, in these xenografts. The ability of
the tumour to use the "salvage" pathway
for thymidine triphosphate synthesis appears
to determine the response of these tumours
in the presence of de novo thymidylate syn-
thesis inhlibition induced bv 5-fluorouracil.
THE PIG AS A MODEL FOR TOXICITY
AND THERAPY TESTING OF CYTO-
TOXIC DRUGS. S. E. BROWNLIE, J. G.
CAMPBELL, K. W. HEAD, P. IMLAH, H. S.
McTAGGART and J. G. MCVIE, Departmient of
Clinical Oncology, Wrestern Infirmary, Glasgow.
A hereditary form of lymphoma associated
with an autosomal recessive gene in Large
White pigs is diagnosable before 3-4 months
of age and fatal by about 15 months. The
suitability of this condition for therapy test-
ing of cytotoxic drugs has been investigated
in toxicity tests using normal pigs. Predniso-
lone, dexamethasone, doxorubicin, cyclo-
phosphamide and vincristine have been
tested as single agents in normal and lympho-
matous pigs. The results of treatment mimic
those expected in humans suggesting that
this is a good animal model for testing newN
drugs and novel schedules of established
drugs. Prednisolone and dexamethasone used
separately produced an increase in serum
albumin arid marked involution ofthe thymus
with "overshoot" on writhdrawal of drugs in
both normal and lymphoma pigs. A similar
effect has been reported in human infants
(Caffey and Silbey (1960) Paediatrics, 26,
762). A striking reduction in circulating
lymphocytes and in the size of lymph nodes
occurred particularly in the lymphoma cases.
Beneficial effects were observed in red cell
picture, neutrophil and platelet counts and
on the general vigour and well-being of
lymphoma cases. These effects were all more
marked Mwith prednisolone than with dexa-
methasone. As in man, doxorubicin was
cumulatively toxic at high doses in both
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normal and lymphoma pigs, producing
stunting of growth, buccal ulceration, alope-
cia, diarrhoea, liver damage, leucopenia,
thrombo-eytopenia and cardiotoxicity.
Remission has been achieved and maintained
for over a year in one case given cyclophos-
phamide and vincristine in combination with
steroids.
CANINE OSTEOSARCOMA: COM-
BINATION CHEMOTHERAPY AND
CLINICAL STAGING. A. M. HENNESS,
Clinical Oncology Service, University of Cali-
fornia, U.S.A. (Introduced by L. N. Owen.)
There are few% reports on the use of anti-
neoplastic drugs in tlherapy for canine
osteosarcoma (OS); results w^ith these agents
have not been encouraging, either because
of their lack of effectiveness against the
disease or due to their significant toxicity
to the host. In this initial study of use of
combination chemotherapy for canine OS,
11 dogs were given cytotoxic drugs following
amputation. Drugs in the standardized 6
month protocol were: Adriamycin (30 mg/
M2), cyclophosphamide (50 mg/M2), and
methotrexate (5 mg/in2) with citrovorum
factor "rescue". A method of clinical staging
of canine OS was devised, based on clinical
and radiographic findings at time of diag-
nosis, to assist retroactively in the evaluating
of therapy and survival data of these 11
animals. Their distribution by clinical stage
was: 1, Ila; 4 Ila; 5, IlIb; and 1, IVb.
At 8 months from time of diagnosis, 7 (64o0)
were alive, and 5 (450 ) were clinically free
of metastases. One (initially stage IIlb)
survived 23 months and then died suddenly
without evidence of OS. A second (stage Ila)
is alive at greater than 41 months from time
of diagnosis. Drugs in the protocol appeared
to be well tolerated.
ANALYSIS OF TWO LYMPHOCYTIC
LAYERS ACHIEVED BY FICOLL-
TRIOSIL GRADIENT SEPARATION.
C. R. PENTYCROSS, Department of Medical
Oncology, Charing Cross HJospital, London.
(Introduced by K. D. Bagshawe.)
During studies on the structuredness of
cytoplasmic matrix (SCM) of lymphocytes,
2 separate interface layers wrere sometimes
obtained with a modified Ficoll-Triosil
gradient separation technique described by
Cercek and Cercek. Two layers were obtained
with 6/10 normal bloods and 4/10 samples
from cancer patients. The two layers have
been compared. In both normal and cancer
samples the upper layers contained from
92-9700 lymphocytes; the lower layers
were more contaminated with non-lympho-
cytic white cells. T (thymus-derived) cells
were more predominant in the upper than
lower in both groups. The SCM test in 8/10
normal subjects and 7/10 cancer patients
confirmed results originally reported by
Cereek et al. ((1974) Br. J. Cancer, 29, 345),
as regards the upper layers, i.e. more response
to phytohaemagglutinin (PHA) than to
myelin basic protein (MBP) in normals and
the reverse in cancer patients. In 2/10 normal
subjects and 3/10 cancer patients the lympho-
cytes were non-responsive to either substance.
The lower layers, in both groups, were
studied where yield permitted, but produced
inconclusive SCM results. In 2 normal
subjects, where the yield permitted study of
PHA blastogenesis, the upper layers showed
more transformation. It is concluded that the
upper layers in all subjects studied contain a
greater proportion of T lymphocytes, are less
contaminated by other white cells, are more
responsive to PHA stimulation in culture and
give more definitive responses in the SCM
test.
SEPARATION OF HUMAN LYMPHO-
CYTES FORMING MOUSE RED CELL
ROSETTES. M. R. POTTER, Paterson
Laboratories, Christie Hospital and Holt
Radium Institute, Manchester. (Introduced by
M. Moore.)
Subpopulations of lymphocytes with
receptors for heterologous erythrocytes can
be identified by rosetting tests as exemplified
by the formation, by human T lymphocytes,
ofrosettes with sheep red blood cells (SRBC).
Rosette formation between human lympho-
cytes and mouse red blood cells (MRBC)
has been described more recently as a marker
for B lymphocytes, or a subpopulation of B
lymphocytes (Stathopoulos and Elliot (1974)
Lancet, i, 600). MRBC rosette formation with
human blood lymphocytes and the separation
of rosette forming cells as a method of B
lymphocyte enrichment has been examined.
Blood lymphocytes were prepared by Ficoll-
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Triosil gradient centrifugation and a small
percentage of these cells (mean value 6%)
formed spontaneous rosettes with MRBC
under conditions similar to those used for
SRBC rosette formation. The proportion of
MRBC rosettes was increased (mean value
16%) by treating the lymphocytes with
neuraminidase before rosetting. Neuramini-
dase treatment of the. MRBC also increased
the number ofrosettes formed, but to a lesser
extent (mean 11%). Double marker tests
demonstrated that lymphocytes forming
MRBC rosettes were immunoglobulin (Ig)
bearing cells, with a high proportion of IgM
bearing cells, but not all Ig bearing cells
formed rosettes. Depletion of the proportion
ofB lymphocytes in the population by nylon
fibre column filtration produced a correspond-
ing fall in the number of MRBC rosette
forming cells. Separation of rosette forming
cells by Ficoll-Triosil gradient centrifugation
gave a pellet population enriched for B
lymphocytes and an interface population
enriched for T lymphocytes. Tests on the
degree of enrichment by re-rosetting with
MRBC produced variable results whereas
testing by SRBC rosette formation showed
a consistent pattern of enrichment.
T AND B CELL POPULATIONS IN
CANCER PATIENTS AND CONTROLS
USING FRESH AND FROZEN LYM-
PHOCYTES. C. H. J. FORD, C. E. NEWMAN
and A. B. CARTER, University Department
of Surgery, Queen Elizabeth Hospital, Bir-
mingham.
Individual E and EAC' rosette tests and
a combination assay for measuring E, EAC'
and mixed rosettes have been used to measure
the numbers ofT and B cells in the peripheral
blood of96 blood transfusion donors (BT), 15
laboratory staff (LS), 36 pre-operative
patients with non-malignant surgical con-
ditions (SP) and 40 cancer patients (CP).
Statistically significant differences were
obtained when comparing the three control
groups (BT, LS, SP) with the CP group in
the individual E test, P < 0-002 (74-7+ 9-7,
79-4 + 8.7, 72-9 : 10 vs 66-2 + 15.5), com-
bination E test, <0-02 to <0.002 (71-8 ±
8-9, 73-1 + 6, 71-9 + 8-8 vs 66-1 ± 10.7),
and when comparing the BT and CP groups
in the individual EAC' test, P < p-01
(11.35 ± 4-3 vs 8-9 + 4-8). A significant
effect of freezing on rosetting ability in both
tests was seen for E rosettes in the SP group
(P < 0.002) and for EAC' rosettes in the BT
group (P < 0-02). In the CP group the
combinationEAC'resultwasalsosignificantly
reduced (P < 0-01). The possibility that the
difference found between the CP and control
groups is due to an effect of longer storage
ofblood from cancer patients prior to testing
is being investigated.
CLINICAL CORRELATES OF IN
VITRO LYMPHOID FUNCTION. N.
THATCHER, N. GASIUNAS and D. CROWTHER,
CRC Department ofMedical Oncology, Christie
Hospital and Holt Radium Institute, Man-
chester.
Lymphoid function was investigated using
the peripheral lymphocyte count, E, EAC
rosettes and also direct, antibody dependent
andPHAinducedlymphocytotoxicity against
51Cr labelled Chang cells.
(a) Influence of Pathology and Stage in
non-Hodgkin lymphoma. Thirty untreated
patients were examined. Peripheral lympho-
cytes, antibody dependent cytotoxicity and
E rosettes were reduced (P < 0-5) compared
with controls. The reduction was statistically
significant forpatients with diffuse pathology.
Patients with nodular pathology, early and
late stage disease, showed some reduction in
test values but were not statistically signifi-
cant.
(b) Influence of Surgical Removal of
Primary Hypernephroma. Eighteen patients
with untreated hypernephroma had signifi-
cantly reduced antibody dependent (P <
0-01) and PHA induced cytotoxicity (P <
0.02) compared with the same patients 14
days post-nephrectomy or with normal
controls. Seven patients had demonstrable
distant metastases pre-operatively, these
patients demonstrated a smaller post-opera-
tive rise in cytotoxicity than the 11 non-
metastaticpatients renderedclinicallytumour
free.
(c) Influence of Chemotherapy and Reduc-
tion in Metastatic Burden. Nineteen patients
with metastatic head and neck, gastric and
bladder carcinoma were treated with pulsed
courses of Adriamycin and 5-Fluorouracil.
The patients were immuno-suppressed (P <
0-02) as indicated by peripheral lymphocyte
count, E, EAC rosettes, direct and antibody
dependent lymphocytotoxicity. Therapy
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which induced an objective reduction in
metastases reduced this pretreatment immu-
nosuppression, but non-responding patients
showed further immunosuppression. Lym-
phoid function as measured by these methods
is therefore related to clinical parameters
of tumour type and tumour burden.
HISTOCHEMICAL DETECTION OF
ABNORMAL SACCHARIDES IN A
CHONDROSARCOMA. R. W. STODDART,
D. D. DZIEWIATKOWSKY and S. FITTON-
JACKSON, Strangeways Research Laboratory,
Cambridge.
The Schwrarm chondrosarcoma of the rat,
which originated as a spontaneous osteochon-
drosarcoma, produces a matrix wi-hich is
abnormally soluble in chaotropic agents and
lacks the repeating sequence of keratan
sulphate. It was maintained by subcutaneous
and intraperitoneal transplantation in hooded
rats and large tumours and occasional
metastases were obtained. Samples were
fixed in anhydrous methanol or Zenker-
acetic acid and paraffin sections were made
by conventional procedures. These were
specifically stained for various sugars by
fluorescent-labelled lectins. Comparisons were
made ith several cartilages of foetal,
juvenile and adult rats. The malignant
chondrocytes showed peculiarities of their
nuclear and surface sugars. The matrix was
highly abnormal and disordered. Soy-bean
agglutinin stained 'cable-like" structures run-
ning through it, which were not seen in any
normal cartilage and wNrhich may have
represented the unsubstituted residues of
N-acetylgalactosamine bv which keratan
sulphate is normally linked to polypeptide.
Concanavalin A stained glycogen intensely
and detected fine fluffy fibrils in the matrix
that may be disordered collagen.
ATHYMIC NUDE MICE: HUSBANDRY
AND TRANSPLANTATION STUDIES.
D. R. MORGAN, Department of Clinical Veter-
inary Medicine, University of Cambridge.
A breeding colony of nude mice was
established using homozygous (nu/nu) males
and heterozygous (nu/+) females, maintained
under simple barrier conditions in isolation
from other animals. Cages, sawdust, food and
water were sterilized and maintenance per-
sonnel wvore surgical gowns, hats and masks,
and the animals wN-ere handled using sterilized
gloves. The room temperature wvas held at
25-27°C and the humidity (uncontrolled)
wvas about 4500. The breeding colony con-
sisted of permanently caged pairs and trios.
Productivity w-as similar to previous reports
(Festing and King, 1974) and although some
perinatal mortality was in evidence a mean
number of 3-5 nu/nu per litter at wveaning
was obtained. In most cases post-partum
matings occurred and the young were
delivered at about the time of weaning the
previous litter. Mortality rates for both the
breeding colony and experimental mice were
lowA. Some cases of the common wasting-
disease syndrome and skin abscesses were
found together wvith occasional instances
of rectal prolapse. The colony has been
maintained for more than 3 years and the
average life-span of homozygotes approached
9-12 months under these conditions. Neoplas-
tic tissues from canine melanoma, osteo-
sarcoma, mammary carcinoma and lympho-
sarcoma were made into cell suspensions and
cultured in RPMI 1640 containing 10% FCS.
Cells from 10 cultures were injected subcu-
taneously in duplicate (5 x 107 cells) into
6-8 week old mice. Transplantation was
successful in 7 cases (14 mice) and growth
was assessed by serial measurement of the
palpable tumours. Tumour samples were
examined histologically and by electron
microscopy and were re-cultured in vitro.
THE AETIOLOGY OF BREAST
CANCER AND THE OESTROGENIC
METABOLITES OF FUSARIA. R.
SCHOENTAL, Department of Pathology, Royal
Veterinary College, University of London.
Reviewing this subject and the many
factors suspected as the causative agents,
MacMahon, Cole and Brown ((1973) J. natn.
Cancer Inst., 50, 21), concluded that the
'nature of the familial factors, genetic or
environmental, is unknown". I suggest that
possible aetiological factors of breast cancer,
which not yet have been taken into considera-
tion. are the non-steroidal oestrogenic secon-
dary metabolites of microorganisms (mainly
of Fusarium spp.) such as zearalenone and
its congeners, which can be found in some
batches of stored grains (compare Stoloff
(1976) in Mycotoxins and other Fungi related
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Food Pr-oblems, Adv. Chem. Series, 149, 23;
Hacking, Rosser and Dervish ((1976) Ann.
Appl. Biol., 84, 7).
The presence in human foodstuffs ofoestro-
genic substances, active by the oral route
could explain the occurrence of familial
breast cancer. Members of a family usually
partake from the same food, hlence wNould be
similarly exposed to its contaminants. It is
worth noting, that the presence ofoestrogenic
substances is not likely to be detected by
taste, or by toxic effects following soon after
ingestion. They act insidiouslv.
Specimens will be shown of Fusarium-
infected maize containing zearalenone, as well
as cultures of Fusarium graminearum on
various media kindly supplied by P. K. C.
Austwick, Nuffield Institute of Comparative
Medicine, The Zoological Society of London,
and ofzearalenone-containing barley obtained
from A. Hacking, Ministry of Agriculture,
Fisheries and Food, Shardlow Hall, Shardlow,
Derby.
ISOLATION OF EPITHELIAL SHEETS
OF HUMAN MAMMARY TUMOUR
CELLS. A. HOWELL, G. K. PANDA and N.
AHKTAR, Departments of Medicine and Cancer
Studies, Birmingham University.
The mean cell yield from 37 human
mammary tumours using the collagenase
di-aggregation technique of Lasfargues (J.
Fogh (ed), Human Tumour Cells in vitro,
Plenum Press, 1975) was 3 90 x 107 eells/g
wet weight with a mean viability of 55.600.
As judged by morphology lymphocytes
comprised 17-8% of the cell population on
average. The presence of lymphocytes w%vas
confirmed by rosetting: all tumours tested
contained cells with Fe and C3 receptors and
also cells which formed E rosettes. Latex
ingesting cells formed approximately 10%
of the total population. Adequate tumour
cell culture was not obtained possibly
because of the presence of lymphocytes
initially and certainly because of fibroblast
overgrowth later. Cells spilled at the time of
cutting of tumours gave a mean yield of
2.42 x 107/g original tumour wet weight
and a mean viability of 17-30. The high
proportion of dead cells interfered with
tumour cell aggregation and adhesion to the
culture surface. When dead cells were
removed by centrifugation through Ficoll-
Triosil the viability increased to a mean of
74.500/ and tumour cellswAere thepredominant
cell type. Viable cells aggregated while on
the Ficoll, and these balls of tumour cells
readily adhered to and spread over the culture
surface to form epithelial islands and sheets
with virtually no fibroblast contamination.
THE ANTI-TUMOUR ACTION OF
SENSITIZED PIG LYMPH NODE
CELLS, MEASURED BY REDUCTION
OF PULMONARY METASTASES IN
MICE: OBSERVATIONS ON THE
NECESSARY SPECIFICITY OF
SENSITIZATION. S. PRICHARD-THOMAS
and M. 0. SYMES, Department of Surgery,
University of Bristol.
Pulmonary tumour metastases were
induced in A-strain mice by i.v. injection of
106 A-strain mammary carcinoma cells. In
some mice, a splenectomy alone wNas per-
formed on Day 6. Other mice received, in
addition, on Day 7 an i.v. injection of
2 x 107 unsensitized or sensitized mono-
nuclear cells, separated from the mesenteric
lymph node chain of a pig. The mice were
killed on Day 14, their lungs fixed in Bouin's
fluid, and the number of metastases counited.
The effect of splenectomy alone, and of
splenectomy plus pig cells, in reducing the
number of metastases, was assessed in com-
parison wvith the numbers in untreated mice.
The results, obtained by an analysis of
variance using pooled data from a number of
experiments, were as follows:
Series I
Treatmetit
Nil
Splenectomy
Splenectomy + pig
cells (unsensitized)
Splenectomy + pig
cells (sensitized to
mouse tumour)
No. of
obser-
vations
27
18
10
23
Significance in
reductionl of
pulmonary meta-
stasis number
<0 05
NS
0-01.
Series II
Nil 42
Splenectomy 27 NS
Splenectomy + pig
cells sensitized to
mouse tumour :34 <0*01
Sensitize(i to
mouse skin 17 (26)* NS
Sensitized to
human tumour 20 (28)* <0*05
* No. of "nil" treatments for this comparison.
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Thus only pig cells sensitized against the
mouse tumour to be treated had a significant
anti-tumour effect. Cells sensitized against a
human tumour (Series II) were only margin-
ally effective, producing the same degree of
reduction in nodule number as splenectomly
alone (Series I). Furthermore, when these
experiments were repeated using pig mono-
nuclear cells stimulated in vitro by culture for
2 days in the presence of PHA, no anti-
tumour effect was obtained. The requirement
for a population of pig cells sensitized against
the tumour to be treated to obtain an anti-
tumour effect, suggests that the mechanism
thereof is an adoptive transfer of immunity
from pig to mouse.
MONONUCLEAR PHAGOCYTE PRO-
LIFERATION IN INFLAMMATION
AND IN VITRO. K. M. WYNNE and W. G.
SPECTOR, Department ofPathology, St Bartho-
lomew's Hospital Medical College, London.
(Introduced by M. Moore.)
Mononuclear phagocyte, or macrophage,
proliferation is a well-established feature of
the chronic inflammatory response, although
its influence upon macrophage activation,
and hence its exact contribution to lesion
progression and/or resolution, remain to be
elucidated. Cultured macrophages, in marked
contrast to their inflammatory counterparts
in vivo, exhibit only minimal levels of DNA
synthesis and proliferation, a fact which can
be exploited in the design of a model system
to investigate the possible existence of local
humoral mitogenic factors in inflammatory
lesions. Exposure of in vitro macrophage
monolayers to cell-free inflammatory exudate
harvested from 4-day-old chronic lesions,
resulted in a stimulation of DNA synthesis,
as evidenced by 3[H]TdR incorporation and
subsequent cell division. No response was
observed prior to the 4th day, but by 7 days
mean 3[H]TdR incorporation by exudate-
treated cells had risen to 60% (range 46-
830) as compared to 10% (range 0-2%) in
the case of control cells, and direct counting
techniquesindicated thatexudate-treated, but
not control, cell populations doubled in
number between the 7th and 10th day of
culture. Further prolongation ofthe prolifera-
tive response was not observed, under the
culture conditions employed in the present
study. Additional evidence for the existence
of macrophage mitogenic activity in inflam-
matory exudate comes from the work of
Adolphe's group in Paris (Adolphe et al.
(1975) Nature, 253, 637), and other studies
have implicated both fibroblasts (Cifone et
al. (1975) Expl Cell Res., 96, 96) and lympho-
cytes (Hadden et al. (1975) Nature, 257, 483)
as potential sources of such factors; thereby
serving to emphasize the probable complexity
of the cellular interrelationships and control
mechanisms which exist in chronic inflam-
mation.
TARGET CELLS OF THE LEUKAE-
MOGENS BUTYL AND METHYL
NITROSOUREA. P. BAINES, Paterson
Laboratories, Christie Hospital and Holt
Radium Institute, Manchester. (Introduced by
M. Moore.)
Lymphoblastic leukaemia developing in
intact mice treated with a single i.v. dose of
MNU or a chronic oral administration of
BNU usually present with thymoma. The
spleen, lymph nodes and liver may also be
involved. Occasionally the leukaemia may
develop in the spleen or lymph nodes in the
absence ofthymic enlargement. Thymectomy
before MNU treatment greatly increases the
induction time and decreases the incidence
ofleukaemias. The incidence ofleukaemias in
thymectomized BNU-treated mice depends
upon the dosing regime. The incidence
decreases and induction time increases if the
dose duration is reduced from continuous
feed to 4 weeks. A similar dose reduction has
little effect on the characteristics of leukae-
mias developing in intact mice. A study of
surface markers on terminal leukaemic cells
shows that in mice with thymoma involve-
ment 6+ve, Ig-ve leukaemias result. If no
thymus enlargement is observed the leukae-
mic cells are 9+ve, Ig-ve, or 0-ve Ig-ve. In
thymectomized mice 0-ve, Ig-ve or Ig+ve
leukaemias may develop. Theleukaemias aris-
ing in intact and thymectomized mice may be
derived from the same or different target
cells. In order to investigate these possibili-
ties, neonatal thymuses were grafted into
thymectomized MNU- or BNU-treated mice.
In most cases the grafted thymus did not
bring about expression of 0 antigen on termi-
nal leukaemic cells. The thymus may be
either the site of a target cell population or
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the site required by the target cell population
for expression of 0 and rapid proliferation.
Thus thymectomy may remove either the
target cell or essential factors required for
maturation of the target cell. Leukaemias
develop in thymectomized hosts, grafted
with neonatal thymus, only after a prolonged
induction time and only rarely express 8
antigen. These results are consistent with
there being a target cell population within
the thymus.
IMMUNOADSORBENT PURIFICA-
TION OF A RAT SARCOMA SPECIFIC
ANTIGEN. V. E. PRESTON and M. R. PRICE,
Cancer Research Campaign Laboratories,
University ofNottingham.
Soluble fractions retaining tumour specific
antigenic activity were prepared from a
3-methylcholanthrene-induced rat sarcoma
by 3 M KCI treatment of tumour tissue.
These extracts, being initially highly hetero-
genous, were fractionated by immunoadsor-
bent procedures involving: (a) the binding of
tumour-specific antigen to syngeneic rat
anti-sarcoma antibodies immobilized upon
Sepharose 4B (Pharmacia, Uppsala), (b)
elution of bound material with 3 M NaSCN
followed by rapid desalting of the antigenic
protein upon Sephadex G25, and (c) passage
of the antigenic protein fraction over an
immunoadsorbent containing normal rat
serum IgG to remove contaminants which
non-specifically bind to substituted Sepharose
matrices. The material so obtained was
characterized by its capacity to neutralize
syngenic tumour specific antibody and to
induce the formation of specific antibody in
immunized rats. This antigenic fraction was
further employed in the preparation ofrabbit
antisera which, following absorption with
unrelated rat sarcoma cells, were rendered
monospecific for the immunizing sarcoma.
Althoughthe material isolated showed limited
heterogeneity as judged by polyacrylamide
gelelectrophoresis andgelfiltration chromato-
graphy, the preparative procedure does allow
the' rapid recovery of fractions 'which are
suitable for further separation and charac-
terization. Also, the availability of these
semi-purified antigen preparations as well
as monospecific heteroantisera mav aid the
development of a quantitative radioimmuno-
assay for tumour specific antigens associated
with chemically induced rat tumours.
EXAMINATION OF THE MEMBRANE
PROTEINS OF HUMAN MELANOMA
CELL LINES. G. P. ROBERTS, R. H.
WHITEHEAD and L. E. HUGHES, University
Department ofSurgery, Welsh National School
ofMedicine, Cardiff.
Cell-surface components play an important
role in regulation of cell growth, antigenicity
and cellular recognition. There is increasing
evidence that the plasma membranes of
tumour cells differ from those ofnormal cells,
but these studies have been largely confined
to laboratory animal cells. Therefore, a study
has been made of the cell surface proteins of
human melanoma cell lines. The cell-surface
proteins were labelled with 125I or 1311 in the
presence of lactoperoxidase, and the labelled
proteins examined by SDS electrophoresis
on a 5-22.5% acrylamide gradient followed
by autoradiography. As many as 24 cell-
surface proteins were detected in the indivi-
dual melanoma cell lines; the molecular
weights of the mercaptoethanol-reduced sub-
units ranged from about 10,000 to 240,000.
There were considerable differences in the
protein profiles of the different melanoma
cell lines, only 10 of the proteins being
common to all 4 melanoma cell lines exam-
ined, and 7 of these proteins were also
detected on the cell surface of fibroblast cell
lines. Attempts were made to detect mela-
noma-specific antigens by affinity chromato-
graphy of extracts of the labelled cells on
immunoadsorbent columns prepared with an
antisera against melanoma cells. Electro-
phoretic examination of the proteins bound
by the immunoadsorbent columns did not
reveal any proteins common to all melanoma
cell lines but absent from other cell lines.
HISTOLOGICAL AND IMMUNO-
LOGICAL RESPONSES IN THE
DRAINING LYMPH NODE DURING
TUMOUR GROWTH IN RATS. G.
ROBINSON.* J. A. JONES and R. C. REES,
*Department ofPathology and Cancer Research
Campaign Laboratories, University ofNotting-
ham.
Little detailed information exists regarding
the response of the draining lymph node to a
developing tumour. Using a transplantable
rat hepatoma (D192A) as a model, the
histological and immunological changes of
lymph nodes regional and distal to the
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tumour site were studied at various stages
following tumour implantation into the
hind limb. Histologically, an early cell-
mediated response was detected in the
lumbar node draining the tumour site. The
T-dependent paracortex showed a marked
proliferation of cells, along with increased
numbers and prominence of post-capillary
venules. This response was maintained for
the first 3 weeks of tumour growth, and then
the paracortex became depleted of lympho-
cytes. Stimulation of the cortical lymph
follicles, with development of active germinal
centres and migration of plasma cells to the
medullary cords, was evident 11 days after
inoculation, and this humoral response
showed no signs of later inactivation. Similar
morphological evidence of cell- and humoral-
mediated responses to tumour growth was
observed in distal nodes, but these were out
of phase with those shown by the draining
node. The response of the draining and distal
lymph nodes was monitored using the in vitro
microcytotoxicity test. Cells from the lumbar
nodes displayed an early cytotoxicity against
D192A and 15-day-old-embryo cell targets,
which decreased during tumour growth.
Cells from the cervical lymph nodes showed
an increasing cytotoxic response towards
these cell targets. In addition, the presence
of serum antibody, specific for the developing
tumour, was detected during the latterstages
of tumour growth by indirect membrane
immunofluorescence.
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